Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18968851,detection limit,"Determination was processed by fluorescence detection (lambda(ex)=480 nm, lambda(em)580 nm); calibration curve was linear over the range 0.01-50 mumoll(-1) (r=0.99965), detection limit was 10 nmoll(-1) (3sigma) and RSD2% (10 readings).",Determination of rhodamine 123 by sequential injection technique for pharmacokinetic studies in the rat placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968851/),,10,980,DB00908,Quinidine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,144,2241,DB00908,Quinidine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,80,2242,DB00908,Quinidine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,104,2243,DB00908,Quinidine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,225,2244,DB00908,Quinidine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,8040,2245,DB00908,Quinidine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,861,2246,DB00908,Quinidine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,1176,2247,DB00908,Quinidine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,6531,2248,DB00908,Quinidine
,15564947,clearance,Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. placebo cotreatment).,Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564947/),[l] / [h],8.3,4294,DB00908,Quinidine
,15564947,clearance,Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. placebo cotreatment).,Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564947/),[l] / [h],6.7,4295,DB00908,Quinidine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],53.9,5277,DB00908,Quinidine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],90.7,5278,DB00908,Quinidine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],16.5,5279,DB00908,Quinidine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],20.0,5280,DB00908,Quinidine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[pg] / [ml],80.8,5281,DB00908,Quinidine
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[pg] / [ml],101,5282,DB00908,Quinidine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[hÂ·ng] / [ml],263,5283,DB00908,Quinidine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[hÂ·ng] / [ml],435,5284,DB00908,Quinidine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[hÂ·ng] / [ml],54.5,5285,DB00908,Quinidine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[hÂ·ng] / [ml],75.7,5286,DB00908,Quinidine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[hÂ·pg] / [ml],467,5287,DB00908,Quinidine
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[hÂ·pg] / [ml],556,5288,DB00908,Quinidine
,25687803,flow rate,"The mobile phase for separation consisted of 5mM ammonium acetate (pH 4.5)/methanol (4:1, v/v) and was delivered at a flow rate of 0.2mL/min.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),[ml] / [min],0.2,6580,DB00908,Quinidine
,25687803,m/,The ion transitions used to monitor analytes were m/z 273âm/z 110 for PLC and m/z 325âm/z 79 for quinidine.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),,273,6581,DB00908,Quinidine
,25687803,m/z,The ion transitions used to monitor analytes were m/z 273âm/z 110 for PLC and m/z 325âm/z 79 for quinidine.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),,325,6582,DB00908,Quinidine
,25687803,m/z,The ion transitions used to monitor analytes were m/z 273âm/z 110 for PLC and m/z 325âm/z 79 for quinidine.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),,79,6583,DB00908,Quinidine
less,25687803,total time for,The total time for chromatographic separation was less than 8min.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),min,8,6584,DB00908,Quinidine
,25687803,recoveries,"Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),%,93.2-99.7,6585,DB00908,Quinidine
,25687803,recoveries,"Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),%,91.4-100.6,6586,DB00908,Quinidine
,25687803,recoveries,"Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),%,93.9-104.7,6587,DB00908,Quinidine
greater,8119501,EC50,Non responders could be predicted by the acute test because they had greater EC50 values of QTc increase: patients with EC50 greater than 2 mg/L were all non responders.,[An experimental model for the rational treatment of arrhythmias: a clinical study with quinidine]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119501/),[mg] / [l],2,7112,DB00908,Quinidine
,7272173,apparent absorption half-life,The mean value for the apparent absorption half-life and time to achieve peak plasma quinidine concentration was 38 +/- 18 min and 2.4 +/- 1.5 h respectively.,Bioavailability of quinidine in congestive heart failure. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272173/),min,38,7303,DB00908,Quinidine
,7272173,time to achieve peak plasma quinidine concentration,The mean value for the apparent absorption half-life and time to achieve peak plasma quinidine concentration was 38 +/- 18 min and 2.4 +/- 1.5 h respectively.,Bioavailability of quinidine in congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7272173/),h,2.4,7304,DB00908,Quinidine
,2702799,AUC,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[Î¼g] / [hÂ·ml],48.2,7447,DB00908,Quinidine
,2702799,AUC,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[Î¼g] / [hÂ·ml],28.6,7448,DB00908,Quinidine
,2702799,CL,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[ml] / [min],94.4,7449,DB00908,Quinidine
,2702799,CL,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[ml] / [min],159.1,7450,DB00908,Quinidine
,2515829,plasma concentrations,The mean plasma concentrations obtained varied from 2.4 +/- 1.1 mg/l at the 20th minute to 0.9 +/- 0.3 mg/l at the 60th minute.,[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515829/),[mg] / [l],2.4,9573,DB00908,Quinidine
,2515829,plasma concentrations,The mean plasma concentrations obtained varied from 2.4 +/- 1.1 mg/l at the 20th minute to 0.9 +/- 0.3 mg/l at the 60th minute.,[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515829/),[mg] / [l],0.9,9574,DB00908,Quinidine
,2515829,refractory periods,"The 3-OH-HQ increased the effective atrial and ventricular refractory periods at the 30th minute (+21.8 +/- 5.5 ms and +22.3 +/- 7 ms, respectively).",[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515829/),ms,21.8,9575,DB00908,Quinidine
,2515829,refractory periods,"The 3-OH-HQ increased the effective atrial and ventricular refractory periods at the 30th minute (+21.8 +/- 5.5 ms and +22.3 +/- 7 ms, respectively).",[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515829/),ms,22.3,9576,DB00908,Quinidine
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],17.0,9894,DB00908,Quinidine
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],11.6,9895,DB00908,Quinidine
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],11.3,9896,DB00908,Quinidine
,6326558,systemic bioavailability,"Uptake and distribution of mexiletine are rapid, systemic bioavailability is about 90%, and tissue distribution is extensive.","Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326558/),%,90,12552,DB00908,Quinidine
,6326558,Elimination half-life,Elimination half-life is 9 to 11 hours after intravenous or oral administration.,"Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326558/),h,9 to 11,12553,DB00908,Quinidine
,954347,absolute bioavailability,"From the ratio of the total area under the plasma concentration-time curves (AUCoral/AUCir), the absolute bioavailability of quinidine ranged from 44% to 89% (mean, 72).",Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),%,44,13585,DB00908,Quinidine
,954347,absolute bioavailability,"From the ratio of the total area under the plasma concentration-time curves (AUCoral/AUCir), the absolute bioavailability of quinidine ranged from 44% to 89% (mean, 72).",Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),%,89,13586,DB00908,Quinidine
,954347,absolute bioavailability,"From the ratio of the total area under the plasma concentration-time curves (AUCoral/AUCir), the absolute bioavailability of quinidine ranged from 44% to 89% (mean, 72).",Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),,72,13587,DB00908,Quinidine
,954347,bioavailability,"In 8 patients, the ratio of the total amount of quinidine excreted in the urine in 48 hr (AUinfinity oral/AUinfinity ir) indicated that the extent of quinidine bioavailability varied form 47% to 96% (mean, 73).",Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),%,47,13588,DB00908,Quinidine
,954347,bioavailability,"In 8 patients, the ratio of the total amount of quinidine excreted in the urine in 48 hr (AUinfinity oral/AUinfinity ir) indicated that the extent of quinidine bioavailability varied form 47% to 96% (mean, 73).",Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),%,96,13589,DB00908,Quinidine
,954347,bioavailability,"In 8 patients, the ratio of the total amount of quinidine excreted in the urine in 48 hr (AUinfinity oral/AUinfinity ir) indicated that the extent of quinidine bioavailability varied form 47% to 96% (mean, 73).",Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),,73,13590,DB00908,Quinidine
,954347,bioavailability,The predicted bioavailability of quindine due to first-pass effects was 76+/-11%.,Absolute quinidine bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954347/),%,76,13591,DB00908,Quinidine
,7408402,total body clearance,Quinine reduced digoxin total body clearance by 26% from 2.98 to 2.22 ml/min/kg (p < 0.03).,Effect of quinine on digoxin kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),[ml] / [kgÂ·min],2,15499,DB00908,Quinidine
,7408402,elimination half-life (t 1/2),"Digoxin elimination half-life (t 1/2) was lengthened from 34.2 to 51.8 hr, reflecting a 32% decrease in digoxin elimination rate constant (p < 0.003).",Effect of quinine on digoxin kinetics. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),h,34.2,15500,DB00908,Quinidine
,7408402,elimination half-life (t 1/2),"Digoxin elimination half-life (t 1/2) was lengthened from 34.2 to 51.8 hr, reflecting a 32% decrease in digoxin elimination rate constant (p < 0.003).",Effect of quinine on digoxin kinetics. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),h,51.8,15501,DB00908,Quinidine
,7408402,x,29 micrograms to x = 772.52 micrograms (p < 0.02).,Effect of quinine on digoxin kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),Î¼g,772.52,15502,DB00908,Quinidine
,7408402,nonrenal clearance,Digoxin nonrenal clearance decreased an average of 55% from 1.2 to 0.55 ml/min/kg (p < 0.05).,Effect of quinine on digoxin kinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),[ml] / [kgÂ·min],1.2,15503,DB00908,Quinidine
,7408402,nonrenal clearance,Digoxin nonrenal clearance decreased an average of 55% from 1.2 to 0.55 ml/min/kg (p < 0.05).,Effect of quinine on digoxin kinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408402/),[ml] / [kgÂ·min],0.55,15504,DB00908,Quinidine
,2229451,clearance,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[l] / [h],20.3,15994,DB00908,Quinidine
,2229451,clearance,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[l] / [h],20.1,15995,DB00908,Quinidine
,2229451,half-life,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,7.9,15996,DB00908,Quinidine
,2229451,half-life,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,7.8,15997,DB00908,Quinidine
,2229451,maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[mg] / [l],1.4,15998,DB00908,Quinidine
,2229451,maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[mg] / [l],1.5,15999,DB00908,Quinidine
,2229451,time to maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,1.5,16000,DB00908,Quinidine
,2229451,time to maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,1.5,16001,DB00908,Quinidine
,9842988,tmax,"Artemether was rapidly absorbed with a mean tmax of 0.8 h (95% confidence interval, CI=0.5-1.1) reaching a mean Cmax of 29 ng/ml (14-45 ng/ml).",The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842988/),h,0.8,17344,DB00908,Quinidine
,9842988,Cmax,"Artemether was rapidly absorbed with a mean tmax of 0.8 h (95% confidence interval, CI=0.5-1.1) reaching a mean Cmax of 29 ng/ml (14-45 ng/ml).",The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842988/),[ng] / [ml],29,17345,DB00908,Quinidine
,9842988,elimination half-life,The mean elimination half-life was 1.3 h (0.8-1.8 h).,The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842988/),h,1.3,17346,DB00908,Quinidine
,2465445,tmax,"Pharmacokinetics of 3-OH-HQ was linear in the range of administered doses, with rapid absorption (tmax 0.5-2.5 h) and distribution (t1/2 alpha 0.8-1.2 h) phases.",Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),h,0.5-2.5,18639,DB00908,Quinidine
,2465445,t1/2 alpha,"Pharmacokinetics of 3-OH-HQ was linear in the range of administered doses, with rapid absorption (tmax 0.5-2.5 h) and distribution (t1/2 alpha 0.8-1.2 h) phases.",Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),h,0.8-1.2,18640,DB00908,Quinidine
,2465445,Elimination half-lives,"Elimination half-lives did not significantly change with the three doses (15 +/- 4.3, 13.7 +/- 3.9, and 13 +/- 2.2 h).",Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),h,15,18641,DB00908,Quinidine
,2465445,Elimination half-lives,"Elimination half-lives did not significantly change with the three doses (15 +/- 4.3, 13.7 +/- 3.9, and 13 +/- 2.2 h).",Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),h,13.7,18642,DB00908,Quinidine
,2465445,Elimination half-lives,"Elimination half-lives did not significantly change with the three doses (15 +/- 4.3, 13.7 +/- 3.9, and 13 +/- 2.2 h).",Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),h,13,18643,DB00908,Quinidine
,2465445,renal clearance,Unchanged 3-OH-HQ was partially eliminated by urine (mean renal clearance 0.24 +/- 0.02 L h-1 kg-1).,Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),[l] / [hÂ·kg],0.24,18644,DB00908,Quinidine
,2465445,QRS duration,PR interval was not significantly modified but QRS duration significantly increased from 91 +/- 7 to 108 +/- 11 ms (p less than 0.001) 2 h after the 900 mg dose.,Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),ms,91,18645,DB00908,Quinidine
,2465445,QRS duration,PR interval was not significantly modified but QRS duration significantly increased from 91 +/- 7 to 108 +/- 11 ms (p less than 0.001) 2 h after the 900 mg dose.,Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2465445/),ms,108,18646,DB00908,Quinidine
,21075975,IC(50),"In addition, P-gp-mediated digoxin transport was inhibited in a concentration-dependent manner by AZD5672 (IC(50) = 32 Î¼M).",The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21075975/),Î¼M,32,21102,DB00908,Quinidine
,2306418,elimination half-life,"A biexponential decline in the log plasma quinidine concentration vs time curves was observed in all subjects, and the mean elimination half-life was 11-12 h.",Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306418/),h,11-12,22260,DB00908,Quinidine
,2123007,steady-state,"Plasma concentration data demonstrated that although encainide metabolism to ODE was partially impaired by quinidine, subsequent 3-methoxy-O-desmethyl encainide formation from ODE was virtually completely inhibited; thus steady-state plasma ODE remained unchanged whereas plasma encainide increased 10-fold (21 +/- 30 to 240 +/- 118 ng/ml; P less than .05).",Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123007/),[ng] / [ml],21,23260,DB00908,Quinidine
,2123007,steady-state,"Plasma concentration data demonstrated that although encainide metabolism to ODE was partially impaired by quinidine, subsequent 3-methoxy-O-desmethyl encainide formation from ODE was virtually completely inhibited; thus steady-state plasma ODE remained unchanged whereas plasma encainide increased 10-fold (21 +/- 30 to 240 +/- 118 ng/ml; P less than .05).",Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123007/),[ng] / [ml],240,23261,DB00908,Quinidine
,7570885,fever clearance times,"Mean fever clearance times (+/- standard errors) were 48.6 +/- 2.7 h and 35.9 +/- 2.2 h in the intrarectal and intramuscular groups, respectively (P = 0.05).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,48.6,24035,DB00908,Quinidine
,7570885,fever clearance times,"Mean fever clearance times (+/- standard errors) were 48.6 +/- 2.7 h and 35.9 +/- 2.2 h in the intrarectal and intramuscular groups, respectively (P = 0.05).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,35.9,24036,DB00908,Quinidine
,7570885,parasite clearance times,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,46.5,24037,DB00908,Quinidine
,7570885,parasite clearance times,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,27.4,24038,DB00908,Quinidine
,7570885,times to achieve 50% reduction,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,7.8,24039,DB00908,Quinidine
,7570885,times to achieve 50% reduction,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,27.4,24040,DB00908,Quinidine
,7570885,times to achieve 50% reduction,"Mean parasite clearance times (+/- standard errors) and mean times to achieve 50% reduction in parasitaemia (+/- standard errors) were similar after intrarectal (46.5 +/- 5.7 h and 7.8 +/- 0.9 h respectively) and intramuscular administration (27.4 +/- 3.6 h and 8.7 +/- 1.7 h, respectively).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,8.7,24041,DB00908,Quinidine
,7570885,Cmax,"after intrarectal administration (2.7 +/- 0.4 h) did not differ significantly from the value after intramuscular administration (1.1 +/- 0.6 h), but Cmax.",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),h,1.1,24042,DB00908,Quinidine
,7570885,area under the concentration-time curve from 0 to 48 h,"and the area under the concentration-time curve from 0 to 48 h were lower (4.9 +/- 0.6 mg/L and 230.0 +/- 9.6 mg/L.h, respectively) than after intramuscular administration (9.1 +/- 1.2 mg/L and 356.0 +/- 4.2 mg/L.h, respectively) (P < 0.001).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),[mg] / [hÂ·l],230.0,24043,DB00908,Quinidine
,7570885,area under the concentration-time curve from 0 to 48 h,"and the area under the concentration-time curve from 0 to 48 h were lower (4.9 +/- 0.6 mg/L and 230.0 +/- 9.6 mg/L.h, respectively) than after intramuscular administration (9.1 +/- 1.2 mg/L and 356.0 +/- 4.2 mg/L.h, respectively) (P < 0.001).",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),[mg] / [hÂ·l],356.0,24044,DB00908,Quinidine
,7570885,bioavailability,"Compared to the intramuscular route, intrarectal Quinimax bioavailability was 40%.(ABSTRACT TRUNCATED AT 250 WORDS)",Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570885/),%,40,24045,DB00908,Quinidine
,7555001,Cmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[Î¼g] / [ml],2.165,24149,DB00908,Quinidine
,7555001,Cmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[Î¼g] / [ml],2.239,24150,DB00908,Quinidine
,7555001,Tmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,2,24151,DB00908,Quinidine
,7555001,Tmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,2.13,24152,DB00908,Quinidine
,7555001,T1/2,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,7.004,24153,DB00908,Quinidine
,7555001,T1/2,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,7.82,24154,DB00908,Quinidine
,7555001,Cls/f,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[ml] / [hÂ·kg],153.63,24155,DB00908,Quinidine
,7555001,Cls/f,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[ml] / [hÂ·kg],134.87,24156,DB00908,Quinidine
,7555001,AUC0-alpha,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[hÂ·Î¼g] / [ml],22.131,24157,DB00908,Quinidine
,7555001,AUC0-alpha,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[hÂ·Î¼g] / [ml],24.321,24158,DB00908,Quinidine
,1587058,apparent volume of distribution (Vd),The mean apparent volume of distribution (Vd) was about 230L.,Pharmacokinetics of quinidine in male patients. A population analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587058/),l,230,24391,DB00908,Quinidine
,3052985,bioavailability,"The bioavailability varies between 40 and 100%: the presence of food may reduce the peak serum concentration, but does not reduce the amount of digoxin absorbed.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),%,40 and 100,31991,DB00908,Quinidine
,3052985,Plasma protein binding,Plasma protein binding varies between 20 and 30%: displacement of digoxin from protein binding sites does not cause significant clinical effects.,"Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),%,20 and 30,31992,DB00908,Quinidine
,3052985,apparent volume of distribution,"The apparent volume of distribution of digoxin varies between 5 and 7.3 L/kg; this may be reduced by, for example, electrolyte abnormalities which reduce digoxin binding to the myocardium.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),[l] / [kg],5 and 7.3,31993,DB00908,Quinidine
,3052985,elimination half-life,"The elimination half-life of digoxin is 36 hours, with 60 to 80% being excreted unchanged, by passive glomerular filtration and active tubular secretion.","Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3052985/),h,36,31994,DB00908,Quinidine
,10456490,Cmax,"The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).",Grapefruit juice has no effect on quinine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456490/),[mg] / [l],0.25,32973,DB00908,Quinidine
,10456490,Cmax,"The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).",Grapefruit juice has no effect on quinine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456490/),[mg] / [l],0.31,32974,DB00908,Quinidine
,10456490,Cmax,"The mean Cmax of the metabolite (0.25+/-0.09 mg l(-1), mean +/- SD) while subjects received full-strength grapefruit juice was significantly less than during the control period (0.31+/-0.06 mg l(-1), P < 0.05) and during the intake of half-strength grapefruit juice (0.31+/-0.07 mg l(-1), P < 0.05).",Grapefruit juice has no effect on quinine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456490/),[mg] / [l],0.31,32975,DB00908,Quinidine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],13.2,35751,DB00908,Quinidine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],9.7,35752,DB00908,Quinidine
,8330461,Renal clearance,Renal clearance of amantadine (13.2 +/- 5.8 L/hr) was significantly inhibited by quinine (9.7 +/- 4.8 L/hr) and quinidine (8.9 +/- 4.0 L/hr) only in male subjects and was not associated with age.,Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330461/),[l] / [h],8.9,35753,DB00908,Quinidine
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB00908,Quinidine
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB00908,Quinidine
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB00908,Quinidine
,2054269,nonrenal clearance,"3. Population pharmacokinetic parameters of quinidine (assuming 100% bioavailability of oral quinidine sulphate) were: nonrenal clearance for patients without severe heart and liver failure 12.6 l h-1, reduction in patients with severe heart or liver failure to 6.8 l h-1, renal clearance (l h-1) related to creatinine clearance (ml min-1), proportionality constant 0.0566, volume of distribution of the central compartment 161 l, maximum serum drug concentration 1.4 h after administration of quinidine sulphate and 6.0 h after administration of quinidine bisulphate.",Population pharmacokinetics of quinidine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054269/),[l] / [h],12.6,37741,DB00908,Quinidine
,2054269,nonrenal clearance,"3. Population pharmacokinetic parameters of quinidine (assuming 100% bioavailability of oral quinidine sulphate) were: nonrenal clearance for patients without severe heart and liver failure 12.6 l h-1, reduction in patients with severe heart or liver failure to 6.8 l h-1, renal clearance (l h-1) related to creatinine clearance (ml min-1), proportionality constant 0.0566, volume of distribution of the central compartment 161 l, maximum serum drug concentration 1.4 h after administration of quinidine sulphate and 6.0 h after administration of quinidine bisulphate.",Population pharmacokinetics of quinidine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054269/),[l] / [h],6.8,37742,DB00908,Quinidine
,2054269,volume of distribution of the central compartment,"3. Population pharmacokinetic parameters of quinidine (assuming 100% bioavailability of oral quinidine sulphate) were: nonrenal clearance for patients without severe heart and liver failure 12.6 l h-1, reduction in patients with severe heart or liver failure to 6.8 l h-1, renal clearance (l h-1) related to creatinine clearance (ml min-1), proportionality constant 0.0566, volume of distribution of the central compartment 161 l, maximum serum drug concentration 1.4 h after administration of quinidine sulphate and 6.0 h after administration of quinidine bisulphate.",Population pharmacokinetics of quinidine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054269/),l,161,37743,DB00908,Quinidine
,27121940,oral absolute bioavailability,Edoxaban oral absolute bioavailability was 61.8%.,Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121940/),%,61.8,38030,DB00908,Quinidine
,27121940,Absolute bioavailability,Absolute bioavailability of edoxaban in healthy volunteers was established (61.8%).,Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121940/),%,61.8,38031,DB00908,Quinidine
,17365275,apparent elimination half-life,[3H]BNP was eliminated with an apparent elimination half-life of 27.5 min after microinjection into the parietal cortex area 2 regions of the rat brain.,P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),min,27.5,39422,DB00908,Quinidine
,17365275,apparent efflux clearance,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [brainÂ·gÂ·min],0.154,39423,DB00908,Quinidine
,17365275,elimination rate constant,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),1Â·min-,2.52 x 10- 2,39424,DB00908,Quinidine
,17365275,distribution volume,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [g],6.11,39425,DB00908,Quinidine
,32360544,orally bioavailable,It was also found that SNAC is orally bioavailable (almost 40%) when dosed to rats.,Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl)amino] Caprylate in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32360544/),%,40,40144,DB00908,Quinidine
,19406953,elimination half-life (t(1/2)),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,176,40583,DB00908,Quinidine
,19406953,apparent elimination rate constant (lambda(z)),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),1/[min],0.0039,40584,DB00908,Quinidine
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,143,40585,DB00908,Quinidine
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,105,40586,DB00908,Quinidine
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,83,40587,DB00908,Quinidine
,19406953,t(1/2),Intravitreal coadministration of quinidine and verapamil resulted in a significant increase in t(1/2) (159 +/- 9 min) and a decrease in lambda(z) (0.0043 +/- 0.0002 min(-1)) of quinidine.,Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,159,40588,DB00908,Quinidine
,19406953,lambda(z),Intravitreal coadministration of quinidine and verapamil resulted in a significant increase in t(1/2) (159 +/- 9 min) and a decrease in lambda(z) (0.0043 +/- 0.0002 min(-1)) of quinidine.,Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),1/[min],0.0043,40589,DB00908,Quinidine
,7368984,bioavailability,"In relation to the plain quinidine tablets, the bioavailability of Systodin and Kinidin Duretter was 96% and 84%, respectively.",Enteric coated quinidine compared to sustained release preparations during repeated administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368984/),%,96,40998,DB00908,Quinidine
,7368984,bioavailability,"In relation to the plain quinidine tablets, the bioavailability of Systodin and Kinidin Duretter was 96% and 84%, respectively.",Enteric coated quinidine compared to sustained release preparations during repeated administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368984/),%,84,40999,DB00908,Quinidine
,7341025,clearance,The dialysis clearance of quinidine was 0.793 ml/min which represented only 0.61% of the total body clearance (154.21 ml/min) of the drug.,Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341025/),[ml] / [min],0.793,42231,DB00908,Quinidine
,7341025,total body clearance,The dialysis clearance of quinidine was 0.793 ml/min which represented only 0.61% of the total body clearance (154.21 ml/min) of the drug.,Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341025/),[ml] / [min],154.21,42232,DB00908,Quinidine
,7341025,elimination half-life,The elimination half-life of quinidine was 5.44 hours.,Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341025/),h,5.44,42233,DB00908,Quinidine
,3997300,elimination half-life,"Coadministration of quinidine sulphate induces a prolongation of digoxin elimination half-life (means +/- SD) from 33.0 +/- 8.0 to 43.9 +/- 6.2 hours, causing an augmentation of 0/48 AUC (means +/- SD) from 37.8 +/- 14.1 to 100.2 +/- 30.4 ng/ml.h.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),h,33.0,44929,DB00908,Quinidine
,3997300,elimination half-life,"Coadministration of quinidine sulphate induces a prolongation of digoxin elimination half-life (means +/- SD) from 33.0 +/- 8.0 to 43.9 +/- 6.2 hours, causing an augmentation of 0/48 AUC (means +/- SD) from 37.8 +/- 14.1 to 100.2 +/- 30.4 ng/ml.h.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),h,43.9,44930,DB00908,Quinidine
,3997300,0/48 AUC,"Coadministration of quinidine sulphate induces a prolongation of digoxin elimination half-life (means +/- SD) from 33.0 +/- 8.0 to 43.9 +/- 6.2 hours, causing an augmentation of 0/48 AUC (means +/- SD) from 37.8 +/- 14.1 to 100.2 +/- 30.4 ng/ml.h.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ng] / [hÂ·ml],37.8,44931,DB00908,Quinidine
,3997300,0/48 AUC,"Coadministration of quinidine sulphate induces a prolongation of digoxin elimination half-life (means +/- SD) from 33.0 +/- 8.0 to 43.9 +/- 6.2 hours, causing an augmentation of 0/48 AUC (means +/- SD) from 37.8 +/- 14.1 to 100.2 +/- 30.4 ng/ml.h.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ng] / [hÂ·ml],100.2,44932,DB00908,Quinidine
,3997300,renal clearance,"This increase in serum digoxin concentration-time course was caused by a decrease of both renal clearance (means +/- SD) from 150.7 +/- 46.5 to 79.0 +/- 23.3 ml/min and of minor importance, total clearance (means +/- SD) from 198.8 +/- 66.4 to 91.7 +/- 21.9 ml/min.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],150.7,44933,DB00908,Quinidine
,3997300,renal clearance,"This increase in serum digoxin concentration-time course was caused by a decrease of both renal clearance (means +/- SD) from 150.7 +/- 46.5 to 79.0 +/- 23.3 ml/min and of minor importance, total clearance (means +/- SD) from 198.8 +/- 66.4 to 91.7 +/- 21.9 ml/min.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],79.0,44934,DB00908,Quinidine
,3997300,total clearance,"This increase in serum digoxin concentration-time course was caused by a decrease of both renal clearance (means +/- SD) from 150.7 +/- 46.5 to 79.0 +/- 23.3 ml/min and of minor importance, total clearance (means +/- SD) from 198.8 +/- 66.4 to 91.7 +/- 21.9 ml/min.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],198.8,44935,DB00908,Quinidine
,3997300,total clearance,"This increase in serum digoxin concentration-time course was caused by a decrease of both renal clearance (means +/- SD) from 150.7 +/- 46.5 to 79.0 +/- 23.3 ml/min and of minor importance, total clearance (means +/- SD) from 198.8 +/- 66.4 to 91.7 +/- 21.9 ml/min.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],91.7,44936,DB00908,Quinidine
,3997300,apparent volume of distribution,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),l,520.1,44937,DB00908,Quinidine
,3997300,apparent volume of distribution,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),l,344.5,44938,DB00908,Quinidine
,3997300,renal,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],61.2,44939,DB00908,Quinidine
,3997300,renal,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],45.7,44940,DB00908,Quinidine
,3997300,clearance,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],61.2,44941,DB00908,Quinidine
,3997300,clearance,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),[ml] / [min],45.7,44942,DB00908,Quinidine
,3997300,elimination half-life,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),h,10.34,44943,DB00908,Quinidine
,3997300,elimination half-life,"A decrease in apparent volume of distribution of digoxin (means +/- SD) from 520.1 +/- 115.2 to 344.5 +/- 78.2 l could also be observed: When digoxin was given additionally, two quinidine-pharmacokinetic parameters were altered: renal quinidine clearance decreased from (means +/- s) 61.2 +/- 11.5 to 45.7 +/- 13.7 ml/min, causing a prolongation of elimination half-life of quinidine (means +/- s) from 10.34 +/- 1.76 to 12.28 +/- 1.23 hours.",Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997300/),h,12.28,44944,DB00908,Quinidine
,431681,elimination half-life,"The elimination half-life of digoxin, although variable, did not change appreciably (42 vs. 44 hours) when quinidine was administered.",Digoxin-quinidine interaction Pharmacokinetic evaluation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/431681/),h,42,45754,DB00908,Quinidine
,431681,elimination half-life,"The elimination half-life of digoxin, although variable, did not change appreciably (42 vs. 44 hours) when quinidine was administered.",Digoxin-quinidine interaction Pharmacokinetic evaluation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/431681/),h,44,45755,DB00908,Quinidine
,431681,total body clearance,"Other pharmacokinetic values were substantially reduced in the presence of quinidine: total body clearance (from 3.08 to 1.96 ml per minute per kilogram), renal clearance (from 1.64 to 1.09 ml per minute per kilogram) and volume of distribution (from 10.87 to 7.35 liters per kilogram).",Digoxin-quinidine interaction Pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/431681/),[ml] / [kgÂ·min],3.08 to 1.96,45756,DB00908,Quinidine
,431681,renal clearance,"Other pharmacokinetic values were substantially reduced in the presence of quinidine: total body clearance (from 3.08 to 1.96 ml per minute per kilogram), renal clearance (from 1.64 to 1.09 ml per minute per kilogram) and volume of distribution (from 10.87 to 7.35 liters per kilogram).",Digoxin-quinidine interaction Pharmacokinetic evaluation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/431681/),[ml] / [kgÂ·min],1.64 to 1.09,45757,DB00908,Quinidine
,431681,volume of distribution,"Other pharmacokinetic values were substantially reduced in the presence of quinidine: total body clearance (from 3.08 to 1.96 ml per minute per kilogram), renal clearance (from 1.64 to 1.09 ml per minute per kilogram) and volume of distribution (from 10.87 to 7.35 liters per kilogram).",Digoxin-quinidine interaction Pharmacokinetic evaluation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/431681/),[l] / [kg],10.87 to 7.35,45758,DB00908,Quinidine
,3190991,oral clearance,2. The oral clearance (7.6 +/- 1.9 vs 4.8 +/- 2.0 ml min-1 kg-1; P less than 0.05) and renal clearance (1.2 +/- 0.3 vs 0.63 +/- 0.25 ml min-1 kg-1; P less than 0.005) or quinidine were lower during steady state than after the single dose.,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[ml] / [kgÂ·min],7.6,49123,DB00908,Quinidine
,3190991,oral clearance,2. The oral clearance (7.6 +/- 1.9 vs 4.8 +/- 2.0 ml min-1 kg-1; P less than 0.05) and renal clearance (1.2 +/- 0.3 vs 0.63 +/- 0.25 ml min-1 kg-1; P less than 0.005) or quinidine were lower during steady state than after the single dose.,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[ml] / [kgÂ·min],4.8,49124,DB00908,Quinidine
,3190991,renal clearance,2. The oral clearance (7.6 +/- 1.9 vs 4.8 +/- 2.0 ml min-1 kg-1; P less than 0.05) and renal clearance (1.2 +/- 0.3 vs 0.63 +/- 0.25 ml min-1 kg-1; P less than 0.005) or quinidine were lower during steady state than after the single dose.,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[ml] / [kgÂ·min],1.2,49125,DB00908,Quinidine
,3190991,renal clearance,2. The oral clearance (7.6 +/- 1.9 vs 4.8 +/- 2.0 ml min-1 kg-1; P less than 0.05) and renal clearance (1.2 +/- 0.3 vs 0.63 +/- 0.25 ml min-1 kg-1; P less than 0.005) or quinidine were lower during steady state than after the single dose.,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[ml] / [kgÂ·min],0.63,49126,DB00908,Quinidine
,3190991,area under the serum concentration vs time curve (AUC),3. The area under the serum concentration vs time curve (AUC) of 3-hydroxyquinidine was greater at steady state than after the single dose (2.0 +/- 0.7 vs 3.0 +/- 0.6 mg l-1 h; P less than 0.05) and its renal clearance was less (3.0 +/- 1.1 vs 1.54 +/- 0.38 ml min-1 kg-1; P less than 0.05).,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[hÂ·mg] / [l],2.0,49127,DB00908,Quinidine
,3190991,area under the serum concentration vs time curve (AUC),3. The area under the serum concentration vs time curve (AUC) of 3-hydroxyquinidine was greater at steady state than after the single dose (2.0 +/- 0.7 vs 3.0 +/- 0.6 mg l-1 h; P less than 0.05) and its renal clearance was less (3.0 +/- 1.1 vs 1.54 +/- 0.38 ml min-1 kg-1; P less than 0.05).,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[hÂ·mg] / [l],3.0,49128,DB00908,Quinidine
,3190991,renal clearance,3. The area under the serum concentration vs time curve (AUC) of 3-hydroxyquinidine was greater at steady state than after the single dose (2.0 +/- 0.7 vs 3.0 +/- 0.6 mg l-1 h; P less than 0.05) and its renal clearance was less (3.0 +/- 1.1 vs 1.54 +/- 0.38 ml min-1 kg-1; P less than 0.05).,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[ml] / [kgÂ·min],3.0,49129,DB00908,Quinidine
,3190991,renal clearance,3. The area under the serum concentration vs time curve (AUC) of 3-hydroxyquinidine was greater at steady state than after the single dose (2.0 +/- 0.7 vs 3.0 +/- 0.6 mg l-1 h; P less than 0.05) and its renal clearance was less (3.0 +/- 1.1 vs 1.54 +/- 0.38 ml min-1 kg-1; P less than 0.05).,The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190991/),[ml] / [kgÂ·min],1.54,49130,DB00908,Quinidine
,3987181,Renal clearance,Renal clearance was 16 L/hr.,Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987181/),[l] / [h],16,51228,DB00908,Quinidine
,3987181,elimination t1/2,"The elimination t1/2 was 12.4 hours, substantially longer than that of quinidine.",Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987181/),h,12.4,51229,DB00908,Quinidine
,3987181,maximum concentrations,No systematic ECG changes were observed in two subjects with maximum concentrations of 55 and 215 micrograms/L.,Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987181/),[Î¼g] / [l],55,51230,DB00908,Quinidine
,3987181,maximum concentrations,No systematic ECG changes were observed in two subjects with maximum concentrations of 55 and 215 micrograms/L.,Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987181/),[Î¼g] / [l],215,51231,DB00908,Quinidine
,3987181,maximum concentrations,"In the other two subjects who achieved higher maximum concentrations (447 and 918 micrograms/L), there was a significant relationship between the length of the corrected QT interval and the serum concentration of 3-OH-quinidine.",Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987181/),[Î¼g] / [l],447,51232,DB00908,Quinidine
,3987181,maximum concentrations,"In the other two subjects who achieved higher maximum concentrations (447 and 918 micrograms/L), there was a significant relationship between the length of the corrected QT interval and the serum concentration of 3-OH-quinidine.",Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987181/),[Î¼g] / [l],918,51233,DB00908,Quinidine
,15848954,apparent elimination half-life,PTZ was eliminated with the apparent elimination half-life of 13.0 min after microinjection into the parietal cortex area 2 region of the rat brain.,In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),min,13.0,53252,DB00908,Quinidine
,15848954,apparent efflux clearance,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[Î¼l] / [brainÂ·gÂ·min],137,53253,DB00908,Quinidine
,15848954,elimination rate constant,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),1/[min],5.35 x 10(-2),53254,DB00908,Quinidine
,15848954,distribution volume,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[ml] / [brainÂ·g],2.56,53255,DB00908,Quinidine
,6858908,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- standard error of the mean) from 25.5 +/- 2.7 to 16.2 +/- 1.4 liters/h (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),[l] / [h],25.5,54585,DB00908,Quinidine
,6858908,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- standard error of the mean) from 25.5 +/- 2.7 to 16.2 +/- 1.4 liters/h (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),[l] / [h],16.2,54586,DB00908,Quinidine
,6858908,half-life,This was reflected in a 55% (range 30 to 109) increase in the mean half-life from 5.8 +/- 0.2 to 9.0 +/- 0.6 hours (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),h,5.8,54587,DB00908,Quinidine
,6858908,half-life,This was reflected in a 55% (range 30 to 109) increase in the mean half-life from 5.8 +/- 0.2 to 9.0 +/- 0.6 hours (p less than 0.05).,Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858908/),h,9.0,54588,DB00908,Quinidine
,2312782,apparent oral clearance,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),[l] / [h],1.93,55170,DB00908,Quinidine
,2312782,apparent oral clearance,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),[l] / [h],2.06,55171,DB00908,Quinidine
,2312782,half-life,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),h,13.5,55172,DB00908,Quinidine
,2312782,half-life,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),h,12.4,55173,DB00908,Quinidine
,576879,half-life,"A considerable degree of variability in quinidine elimination was noted, with half-life values ranging from 2.71 to 8.12 hr (mean half-life of 5.36 hr).",Comparative bioavaiability of four commercial quinidine sulfate tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576879/),h,2.71 to 8.12,57777,DB00908,Quinidine
,576879,half-life,"A considerable degree of variability in quinidine elimination was noted, with half-life values ranging from 2.71 to 8.12 hr (mean half-life of 5.36 hr).",Comparative bioavaiability of four commercial quinidine sulfate tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576879/),h,5.36,57778,DB00908,Quinidine
,3621790,elimination half-life,"Because of a small volume of distribution, the elimination half-life of quinidine-N-oxide was only 2.5 +/- 0.28 hours (mean +/- SD), considerably shorter than that of quinidine.",Kinetics and dynamics of quinidine-N-oxide in healthy subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621790/),h,2.5,58245,DB00908,Quinidine
,3621790,renal clearance,The renal clearance was 1.3 +/- 0.3 L/hr.,Kinetics and dynamics of quinidine-N-oxide in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621790/),[l] / [h],1.3,58246,DB00908,Quinidine
,3621790,free fraction,The free fraction in serum was 3.3% +/- 0.83%.,Kinetics and dynamics of quinidine-N-oxide in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621790/),%,3.3,58247,DB00908,Quinidine
,6144760,peak concentration,Quinidine induced a marked increase to give a mean peak concentration of ajmaline which increased from 0.018 micrograms ml-1 after a single administration to 0.141 micrograms ml-1 in combination with quinidine.,Quinidine-induced rise in ajmaline plasma concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144760/),[Î¼g] / [ml],0.018,59095,DB00908,Quinidine
,6144760,peak concentration,Quinidine induced a marked increase to give a mean peak concentration of ajmaline which increased from 0.018 micrograms ml-1 after a single administration to 0.141 micrograms ml-1 in combination with quinidine.,Quinidine-induced rise in ajmaline plasma concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144760/),[Î¼g] / [ml],0.141,59096,DB00908,Quinidine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),Î¼M,11,63198,DB00908,Quinidine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),Î¼M,83,63199,DB00908,Quinidine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),Î¼M,24,63200,DB00908,Quinidine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),Î¼M,20,63201,DB00908,Quinidine
,7946933,liver:water partition ratios,"4. The in vitro data predict 29% inhibition of ALP clearance at mean FLU and NOR plasma concentrations of 77 ng ml-1 and 72 ng ml-1, respectively, after correction for liver:water partition ratios in the range of 12-14.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),,12-14,63202,DB00908,Quinidine
,7946933,Ki,"5. Ketoconazole was a potent inhibitor of ALP metabolism in vitro (Ki = 0.046 microM), suggesting that ALP hydroxylation is mediated by the cytochrome P450-3A sub-family.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),Î¼M,0.046,63203,DB00908,Quinidine
,7946933,Ki,Quinidine was a weak inhibitor (Ki = 626 microM).,"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),Î¼M,626,63204,DB00908,Quinidine
,6988137,apparent volume of distribution,"Typical ranges for kinetic properites of quinidine in healthy persons are: apparent volume of distribution 2.0 to 3.5 litres/kg; elimination half-life 5 to 12 hours; clearance, 2.5 to 5.0 ml/min/kg.",Clinical pharmacokinetics of quinidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6988137/),[l] / [kg],2.0 to 3.5,65514,DB00908,Quinidine
,6988137,elimination half-life,"Typical ranges for kinetic properites of quinidine in healthy persons are: apparent volume of distribution 2.0 to 3.5 litres/kg; elimination half-life 5 to 12 hours; clearance, 2.5 to 5.0 ml/min/kg.",Clinical pharmacokinetics of quinidine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6988137/),h,5 to 12,65515,DB00908,Quinidine
,6988137,clearance,"Typical ranges for kinetic properites of quinidine in healthy persons are: apparent volume of distribution 2.0 to 3.5 litres/kg; elimination half-life 5 to 12 hours; clearance, 2.5 to 5.0 ml/min/kg.",Clinical pharmacokinetics of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6988137/),[ml] / [kgÂ·min],2.5 to 5.0,65516,DB00908,Quinidine
,6988137,Absolute systemic availability,Absolute systemic availability generally is 70% or greater.,Clinical pharmacokinetics of quinidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6988137/),%,70,65517,DB00908,Quinidine
,31678424,Km,"Seletalisib was found to be actively transported by rodent and human P-gp in vitro (transfected LLC-PK1 cells; Km of ca. 20 ÂµM), with minimal or no affinity for the other tested transporters.",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),Î¼M,20,67423,DB00908,Quinidine
,31678424,"Kp,uu","Restricted brain penetration was also observed in cynomolgus monkeys (single oral dosing at 30 mg kg-1) using brain microdialysis and cerebrospinal fluid sampling (Kp,uu of 0.09 and 0.24, respectively).",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),,0.09,67424,DB00908,Quinidine
,31678424,"Kp,uu","Restricted brain penetration was also observed in cynomolgus monkeys (single oral dosing at 30 mg kg-1) using brain microdialysis and cerebrospinal fluid sampling (Kp,uu of 0.09 and 0.24, respectively).",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),,0.24,67425,DB00908,Quinidine
,31678424,IC50,"In vitro, CsA inhibited the active transport of seletalisib with an IC50 of 0.13 ÂµM.",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),Î¼M,0.13,67426,DB00908,Quinidine
,882146,t0.5alpha,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,3.0,67998,DB00908,Quinidine
,882146,t0.5alpha,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,2.5,67999,DB00908,Quinidine
,882146,t0.5beta,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,16,68000,DB00908,Quinidine
,882146,t0.5beta,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,20,68001,DB00908,Quinidine
,882146,volume of distribution Vdbeta,"High tissue accumulation of both alkaloids was found in lung, liver, and heart and this is also reflected by the volume of distribution Vdbeta, which was 136 ml for ajmaline and 116 ml for quinidine (body weight of the mice = 31 g).",The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),ml,136,68002,DB00908,Quinidine
,882146,volume of distribution Vdbeta,"High tissue accumulation of both alkaloids was found in lung, liver, and heart and this is also reflected by the volume of distribution Vdbeta, which was 136 ml for ajmaline and 116 ml for quinidine (body weight of the mice = 31 g).",The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),ml,116,68003,DB00908,Quinidine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.20,69837,DB00908,Quinidine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.61,69838,DB00908,Quinidine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.13,69839,DB00908,Quinidine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.88,69840,DB00908,Quinidine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.74,69841,DB00908,Quinidine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.59,69842,DB00908,Quinidine
,18651556,bioavailability,"Thus, the bioavailability of TAK-427 after oral administration in rats (7.3%) markedly increased when co-administered with P-gp inhibitors (28.6-57.6%).",Marked impact of P-glycoprotein on the absorption of TAK-427 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651556/),%,7.3,73314,DB00908,Quinidine
,18651556,bioavailability,"Thus, the bioavailability of TAK-427 after oral administration in rats (7.3%) markedly increased when co-administered with P-gp inhibitors (28.6-57.6%).",Marked impact of P-glycoprotein on the absorption of TAK-427 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651556/),%,28.6-57.6,73315,DB00908,Quinidine
,7213521,steady state plasma concentration,3 The mean steady state plasma concentration of digoxin increased from 0.7 to 1.3 nmol/l after quinidine administration.,Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213521/),[nM] / [l],0.7,75970,DB00908,Quinidine
,7213521,steady state plasma concentration,3 The mean steady state plasma concentration of digoxin increased from 0.7 to 1.3 nmol/l after quinidine administration.,Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213521/),[nM] / [l],1.3,75971,DB00908,Quinidine
,7213521,elimination half life,The mean elimination half life of digoxin increased from 49 to 72 h during quinidine.,Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213521/),h,49,75972,DB00908,Quinidine
,7213521,elimination half life,The mean elimination half life of digoxin increased from 49 to 72 h during quinidine.,Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213521/),h,72,75973,DB00908,Quinidine
,8739026,time to maximum concentration (tmax),"There was no significant difference in pharmacokinetic parameters of quinidine when administered with grapefruit juice or water, except for time to maximum concentration (tmax), which was 1.6 hours after administration with water and 3.3 hours after administration with grapefruit juice.",Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739026/),h,1.6,77228,DB00908,Quinidine
,8739026,time to maximum concentration (tmax),"There was no significant difference in pharmacokinetic parameters of quinidine when administered with grapefruit juice or water, except for time to maximum concentration (tmax), which was 1.6 hours after administration with water and 3.3 hours after administration with grapefruit juice.",Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739026/),h,3.3,77229,DB00908,Quinidine
,25168620,Absolute bioavailability,Absolute bioavailability of edoxaban was estimated as 58.3 %.,Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25168620/),%,58.3,77842,DB00908,Quinidine
,10746167,kE0,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),1/[min],2.72 x 10(-4),78123,DB00908,Quinidine
,10746167,Emax,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),ms,27.1,78124,DB00908,Quinidine
,10746167,EC50,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),[ng] / [ml],0.376,78125,DB00908,Quinidine
,10746167,kE0,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),1/[min],0.148,78126,DB00908,Quinidine
,10746167,K,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),[mlÂ·ms] / [Î¼g],8.41,78127,DB00908,Quinidine
,1451729,volume of distribution,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[l] / [kg],7.9,79617,DB00908,Quinidine
,1451729,volume of distribution,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[l] / [kg],7.4,79618,DB00908,Quinidine
,1451729,half-life,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),h,8.8,79619,DB00908,Quinidine
,1451729,half-life,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),h,10.7,79620,DB00908,Quinidine
,1451729,total clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kgÂ·min],10.6,79621,DB00908,Quinidine
,1451729,total clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kgÂ·min],8.1,79622,DB00908,Quinidine
,1451729,non-renal clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kgÂ·min],7.2,79623,DB00908,Quinidine
,1451729,non-renal clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kgÂ·min],5.2,79624,DB00908,Quinidine
,1451729,renal clearance,"These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kgÂ·min],3.5,79625,DB00908,Quinidine
,1451729,renal clearance,"These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kgÂ·min],2.9,79626,DB00908,Quinidine
,2484920,peak blood levels,"Mean peak blood levels of dihydroquinidine and quinidine were 1.06 +/- 0.34 and 2.15 +/- 0.96 micrograms/ml, respectively.",Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484920/),[Î¼g] / [ml],1.06,81958,DB00908,Quinidine
,2484920,peak blood levels,"Mean peak blood levels of dihydroquinidine and quinidine were 1.06 +/- 0.34 and 2.15 +/- 0.96 micrograms/ml, respectively.",Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484920/),[Î¼g] / [ml],2.15,81959,DB00908,Quinidine
,2484920,Steady-state peak plasma concentrations,"Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10 +/- 0.41 and 2.24 +/- 1.13 micrograms/ml, respectively.",Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484920/),[Î¼g] / [ml],1.10,81960,DB00908,Quinidine
,2484920,Steady-state peak plasma concentrations,"Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10 +/- 0.41 and 2.24 +/- 1.13 micrograms/ml, respectively.",Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484920/),[Î¼g] / [ml],2.24,81961,DB00908,Quinidine
,499305,half-life,"The half-life of the fast and slow dispositional processes was 4.42 +/- 1.81 min and 6.52 +/- 2.40 h, respectively.",Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),min,4.42,82378,DB00908,Quinidine
,499305,half-life,"The half-life of the fast and slow dispositional processes was 4.42 +/- 1.81 min and 6.52 +/- 2.40 h, respectively.",Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),h,6.52,82379,DB00908,Quinidine
,499305,central compartment volume,The central compartment volume for dihydroquinidine in these patients was 0.44 +/- 0.11 l/kg with an overall apparent volume of distribution of 1.14 +/- 0.38 l/kg.,Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),[l] / [kg],0.44,82380,DB00908,Quinidine
,499305,overall apparent volume of distribution,The central compartment volume for dihydroquinidine in these patients was 0.44 +/- 0.11 l/kg with an overall apparent volume of distribution of 1.14 +/- 0.38 l/kg.,Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),[l] / [kg],1.14,82381,DB00908,Quinidine
,499305,total body plasma clearance,The computed values of total body plasma clearance of dihydroquinidine ranged from 1.29 to 2.69 ml/min/kg with a mean value of 1.94 +/- 0.60 ml/min/kg.,Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),[ml] / [kgÂ·min],1.29 to 2.69,82382,DB00908,Quinidine
,499305,total body plasma clearance,The computed values of total body plasma clearance of dihydroquinidine ranged from 1.29 to 2.69 ml/min/kg with a mean value of 1.94 +/- 0.60 ml/min/kg.,Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),[ml] / [kgÂ·min],1.94,82383,DB00908,Quinidine
,499305,renal clearance,The estimated value of renal clearance was 0.314 +/- 0.129 ml/min/kg.,Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499305/),[ml] / [kgÂ·min],0.314,82384,DB00908,Quinidine
greater,8800971,oral bioavailability,"The mean +/- S.D. oral bioavailability of quinidine was, unexpectedly, greater than 100% (147 +/- 44%).",Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8800971/),%,100,83319,DB00908,Quinidine
,8800971,oral bioavailability,"The mean +/- S.D. oral bioavailability of quinidine was, unexpectedly, greater than 100% (147 +/- 44%).",Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8800971/),%,147,83320,DB00908,Quinidine
,925112,recovery,The recovery from plasma was from 96 to 103% for quinidine and from 93.5 to 98.5% for dihydroquinidine.,Specific thin-layer chromatographic method for the determination of quinidine in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/925112/),%,96 to 103,84483,DB00908,Quinidine
,925112,recovery,The recovery from plasma was from 96 to 103% for quinidine and from 93.5 to 98.5% for dihydroquinidine.,Specific thin-layer chromatographic method for the determination of quinidine in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/925112/),%,93.5 to 98.5,84484,DB00908,Quinidine
,9797797,Peak serum concentrations,Peak serum concentrations of selegiline were reached rapidly and ranged from 1 to 32 nmol/L.,CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[nM] / [l],1 to 32,84693,DB00908,Quinidine
,9797797,50% inhibitory concentration,"The inhibitory potency of selegiline, desmethylselegiline, and l-methamphetamine toward dextromethorphan O-demethylase was very low (50% inhibitory concentration values from 160 to 580 mumol/L).",CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[Î¼M] / [l],160 to 580,84694,DB00908,Quinidine
,8841148,area under the curve,"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[hÂ·ng] / [ml],7414,86988,DB00908,Quinidine
,8841148,area under the curve,"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[hÂ·ng] / [ml],"11,213",86989,DB00908,Quinidine
,8841148,terminal elimination half-life (t1/2),"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),h,6.8,86990,DB00908,Quinidine
,8841148,terminal elimination half-life (t1/2),"Pretreatment with diltiazem significantly (p < 0.05) increased the area under the curve of quinidine from 7414 +/- 1965 to 11,213 +/- 2610 ng.hr/ml and increased its terminal elimination half-life (t1/2) from 6.8 +/- 1.1 to 9.3 +/- 1.5 hours.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),h,9.3,86991,DB00908,Quinidine
,8841148,oral clearance,"Its oral clearance was decreased from 0.39 +/- 0.1 to 0.25 +/- 0.1 L/hr/kg, whereas the maximal concentration was not significantly affected.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[l] / [hÂ·kg],0.39,86992,DB00908,Quinidine
,8841148,oral clearance,"Its oral clearance was decreased from 0.39 +/- 0.1 to 0.25 +/- 0.1 L/hr/kg, whereas the maximal concentration was not significantly affected.",Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841148/),[l] / [hÂ·kg],0.25,86993,DB00908,Quinidine
,8983859,t1/2z,"There is increased plasma protein binding, predominantly to alpha 1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z = 11 hours, quinidine t1/2z = 8 hours) are prolonged by 50%.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),h,11,87263,DB00908,Quinidine
,8983859,t1/2z,"There is increased plasma protein binding, predominantly to alpha 1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z = 11 hours, quinidine t1/2z = 8 hours) are prolonged by 50%.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),h,8,87264,DB00908,Quinidine
more,8983859,bioavailability,Quinine is well absorbed by mouth or following intramuscular injection even in severe cases of malaria (estimated bioavailability more than 85%).,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),%,85,87265,DB00908,Quinidine
more,8983859,total apparent volume of distribution (Vd),"Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),[l] / [kg],100,87266,DB00908,Quinidine
,8983859,terminal elimination half-life,"Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),month,1 to 2,87267,DB00908,Quinidine
exceeds,8983859,Oral bioavailability,Oral bioavailability exceeds 75%.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),%,75,87268,DB00908,Quinidine
,8983859,Vd,Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),[l] / [kg],17 to 34,87269,DB00908,Quinidine
,8983859,terminal elimination half-life,Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),weeks,1 to 3,87270,DB00908,Quinidine
,1277713,peak concentration,"After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 +/-0.22 mug/ml (+/-SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 +/-0.12 mug/ml.",Disposition kinetics of two oral forms of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),[Î¼g] / [ml],2.13,88465,DB00908,Quinidine
,1277713,peak concentration,"After a single dose of two tablets of quinidine sulfate (400 mg), the average peak concentration was 2.13 +/-0.22 mug/ml (+/-SEM); following two tablets of the slow-release form, the average peak concentration was 1.17 +/-0.12 mug/ml.",Disposition kinetics of two oral forms of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),[Î¼g] / [ml],1.17,88466,DB00908,Quinidine
,1277713,T-max,T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate.,Disposition kinetics of two oral forms of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),h,2,88467,DB00908,Quinidine
,1277713,T-max,T-max was approximately 2 hr with quinidine sulfate and 4 hr with quinidine bisulfate.,Disposition kinetics of two oral forms of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),h,4,88468,DB00908,Quinidine
,1277713,Total body clearance,Total body clearance was 0.36 L/kg-hr and renal clearance was 117 +/-22ml/min for both.,Disposition kinetics of two oral forms of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),[l] / [kg-hr],0.36,88469,DB00908,Quinidine
,1277713,renal clearance,Total body clearance was 0.36 L/kg-hr and renal clearance was 117 +/-22ml/min for both.,Disposition kinetics of two oral forms of quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),[ml] / [min],117,88470,DB00908,Quinidine
,1277713,half-life,"Based on the mean estimates of quinidine half-life of 6 hr, a rapid method for achieving steady-state levels of quinidine would be to give an initial dose twice that of the maintenance dose.",Disposition kinetics of two oral forms of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277713/),h,6,88471,DB00908,Quinidine
,11994058,Cmax,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[ng] / [ml],12.55,89047,DB00908,Quinidine
,11994058,Cmax,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[ng] / [ml],5.38,89048,DB00908,Quinidine
,11994058,CLoral,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [hÂ·kg],0.49,89049,DB00908,Quinidine
,11994058,CLoral,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [hÂ·kg],1.07,89050,DB00908,Quinidine
,11994058,Cmax,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),,13.94,89051,DB00908,Quinidine
,11994058,CLoral,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [hÂ·kg],0.22,89052,DB00908,Quinidine
,11994058,elimination half-life,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),h,18.0,89053,DB00908,Quinidine
,11994058,elimination half-life,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),h,29.3,89054,DB00908,Quinidine
,11994058,CLoral,Administration of quinidine decreased CLoral for (R)-(-)-chlorpheniramine to 0.60+/-0.10 l h-1 kg-1 (P<0.005).,The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [hÂ·kg],0.60,89055,DB00908,Quinidine
,8582470,total clearance,"In the EM, the total clearance, the clearance via 3-hydroxylation and the clearance via N-oxidation, were 33, 3.7 and 0.23 l.h-1, respectively.",Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582470/),[l] / [h],33,89211,DB00908,Quinidine
,8582470,clearance via,"In the EM, the total clearance, the clearance via 3-hydroxylation and the clearance via N-oxidation, were 33, 3.7 and 0.23 l.h-1, respectively.",Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582470/),[l] / [h],3.7,89212,DB00908,Quinidine
,8582470,clearance via,"In the EM, the total clearance, the clearance via 3-hydroxylation and the clearance via N-oxidation, were 33, 3.7 and 0.23 l.h-1, respectively.",Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582470/),[l] / [h],0.23,89213,DB00908,Quinidine
,8582470,clearance,"In the EM, the total clearance, the clearance via 3-hydroxylation and the clearance via N-oxidation, were 33, 3.7 and 0.23 l.h-1, respectively.",Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582470/),[l] / [h],0.23,89214,DB00908,Quinidine
,23061481,B/P ratio,"Atenolol, a non P-gp substrate, exhibited poor brain penetration in the presence or absence of elacridar in both species (B/P ratio ~ 0.1).",A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061481/),,0.1,89418,DB00908,Quinidine
,7931489,Css,TPT Css values ranged from 4.8 to 72.5 nmol/L.,Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931489/),[nM] / [l],4.8 to 72.5,90740,DB00908,Quinidine
,7931489,LD90,"Colony-forming assays showed that the TPT LD90 (dose that inhibits the growth of leukemia blast colonies by 90%) values for blasts varied from 6 to 22 nmol/L, a range that overlapped with TPT Css values.",Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931489/),[nM] / [l],6 to 22,90741,DB00908,Quinidine
,31868554,Vmax,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 Â± 11.20 pmol/min/mg, 11.10 Â± 1.07 Î¼M, and 23.10 Â± 1.32 Î¼L/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),[pM] / [mgÂ·min],256.41,92177,DB00908,Quinidine
,31868554,Km,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 Â± 11.20 pmol/min/mg, 11.10 Â± 1.07 Î¼M, and 23.10 Â± 1.32 Î¼L/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),Î¼M,11.10,92178,DB00908,Quinidine
,31868554,CLint,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 Â± 11.20 pmol/min/mg, 11.10 Â± 1.07 Î¼M, and 23.10 Â± 1.32 Î¼L/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),[Î¼l] / [mgÂ·min],23.10,92179,DB00908,Quinidine
,14962511,half-life for total elimination,The half-life for total elimination was calculated to be 16.3 days with 99% eliminated by 97 days.,Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962511/),d,16.3,94938,DB00908,Quinidine
,8216438,area under the plasma concentration-time curve,"Concurrent administration of LNC-834 decreased significantly the area under the plasma concentration-time curve of warfarin (117,889 +/- 25,010 (A) vs. 125,294 +/- 22,314 ng/ml.h (B); p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ng] / [hÂ·ml],"117,889",94998,DB00908,Quinidine
,8216438,area under the plasma concentration-time curve,"Concurrent administration of LNC-834 decreased significantly the area under the plasma concentration-time curve of warfarin (117,889 +/- 25,010 (A) vs. 125,294 +/- 22,314 ng/ml.h (B); p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ng] / [hÂ·ml],"125,294",94999,DB00908,Quinidine
,8216438,apparent oral clearance (CL/f),"Thus, a significant increase in apparent oral clearance (CL/f) of warfarin in the presence of LNC-834 was determined (3.98 +/- 0.63 vs. 3.71 +/- 0.50 ml/min; p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ml] / [min],3.98,95000,DB00908,Quinidine
,8216438,apparent oral clearance (CL/f),"Thus, a significant increase in apparent oral clearance (CL/f) of warfarin in the presence of LNC-834 was determined (3.98 +/- 0.63 vs. 3.71 +/- 0.50 ml/min; p = 0.0488).","Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216438/),[ml] / [min],3.71,95001,DB00908,Quinidine
,7480098,bioavailability,Administration of the test drugs in combination slightly increased the bioavailability of both--nifedipine [N] to 18% and quinidine [Q] to 16%--and decreased the clearance of both drugs.,Pharmacokinetic interactions of nifedipine and quinidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7480098/),%,18,96483,DB00908,Quinidine
,7480098,bioavailability,Administration of the test drugs in combination slightly increased the bioavailability of both--nifedipine [N] to 18% and quinidine [Q] to 16%--and decreased the clearance of both drugs.,Pharmacokinetic interactions of nifedipine and quinidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7480098/),%,16,96484,DB00908,Quinidine
,2792169,maximum concentrations,2-OH-Imipramine and 2-OH-desipramine were detected in plasma before (maximum concentrations 30-100 nmol.l-1) but not during quinidine.,Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792169/),[nM] / [l],30-100,97307,DB00908,Quinidine
,1880724,systemic clearance,"After separate dosage, systemic clearance of quinine tended to be greater than that of quinidine (714 +/- 299 versus 422 +/- 146 mL/min, p = 0.08).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],714,99435,DB00908,Quinidine
,1880724,systemic clearance,"After separate dosage, systemic clearance of quinine tended to be greater than that of quinidine (714 +/- 299 versus 422 +/- 146 mL/min, p = 0.08).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],422,99436,DB00908,Quinidine
,1880724,Cf:Cm ratios,"After separate dosage, fetal total concentrations (Cf) of quinine and quinidine were substantially lower than maternal total concentrations, as reflected in Cf:Cm ratios of 0.15 +/- 0.06 versus 0.10 +/- 0.08, respectively.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.15,99437,DB00908,Quinidine
,1880724,Cf:Cm ratios,"After separate dosage, fetal total concentrations (Cf) of quinine and quinidine were substantially lower than maternal total concentrations, as reflected in Cf:Cm ratios of 0.15 +/- 0.06 versus 0.10 +/- 0.08, respectively.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.10,99438,DB00908,Quinidine
,1880724,Cfu/Cmu,"Similarly, fetal unbound concentrations (Cfu) were substantially lower than maternal unbound concentrations (Cmu; Cfu/Cmu = 0.46 +/- 0.09 for quinine and 0.23 +/- 0.09 for quinidine).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.46,99439,DB00908,Quinidine
,1880724,Cfu/Cmu,"Similarly, fetal unbound concentrations (Cfu) were substantially lower than maternal unbound concentrations (Cmu; Cfu/Cmu = 0.46 +/- 0.09 for quinine and 0.23 +/- 0.09 for quinidine).",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.23,99440,DB00908,Quinidine
,1880724,renal clearances,"Fetal renal clearances of quinine and quinidine were similar (0.34 +/- 0.24 mL/min versus 0.38 +/- 0.24 mL/min) and less than that of endogenous creatinine, indicating the absence of net renal tubular secretion.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],0.34,99441,DB00908,Quinidine
,1880724,renal clearances,"Fetal renal clearances of quinine and quinidine were similar (0.34 +/- 0.24 mL/min versus 0.38 +/- 0.24 mL/min) and less than that of endogenous creatinine, indicating the absence of net renal tubular secretion.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),[ml] / [min],0.38,99442,DB00908,Quinidine
,1880724,Cf:Cm,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.48,99443,DB00908,Quinidine
,1880724,Cf:Cm,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.31,99444,DB00908,Quinidine
,1880724,Cfu:Cmu,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.73,99445,DB00908,Quinidine
,1880724,Cfu:Cmu,"After simultaneous dosage of quinine and quinidine, Cf:Cm (0.48 +/- 0.24 and 0.31 +/- 0.19, respectively) and Cfu:Cmu (0.73 +/- 0.14 and 0.52 +/- 0.20, respectively) were greater than for separate dosages.",Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880724/),,0.52,99446,DB00908,Quinidine
,2761143,Plasma half-life,Plasma half-life of intravenous quinidine was 1.28 +/- 0.492 (0.41-1.65) hr.,Pharmacokinetics of quinidine sulfate in dairy cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761143/),h,1.28,100121,DB00908,Quinidine
,2761143,Total body clearance,"Total body clearance was 58.7 +/- 24.49 ml/min/kg, although renal quinidine clearance was 0.76 +/- 0.441 ml/min/kg.",Pharmacokinetics of quinidine sulfate in dairy cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761143/),[ml] / [kgÂ·min],58.7,100122,DB00908,Quinidine
,2761143,renal quinidine clearance,"Total body clearance was 58.7 +/- 24.49 ml/min/kg, although renal quinidine clearance was 0.76 +/- 0.441 ml/min/kg.",Pharmacokinetics of quinidine sulfate in dairy cattle. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761143/),[ml] / [kgÂ·min],0.76,100123,DB00908,Quinidine
,2761143,plasma concentration,They showed plasma concentration of 2.3 +/- 1.59 mg/l when therapeutic effect was observed.,Pharmacokinetics of quinidine sulfate in dairy cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761143/),[mg] / [l],2.3,100124,DB00908,Quinidine
,1981549,AUC ratio,"After all routes of administration, the AUC for the (-)-enantiomer was significantly higher than that of its antipode: the mean +/- SD values of (-):(+) AUC ratio were 1.99 +/- 0.228, 2.52 +/- 0.525, and 3.54 +/- 1.12 for the iv, ip, and po data, respectively.",Pharmacokinetics of propafenone enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,1.99,102342,DB00908,Quinidine
,1981549,AUC ratio,"After all routes of administration, the AUC for the (-)-enantiomer was significantly higher than that of its antipode: the mean +/- SD values of (-):(+) AUC ratio were 1.99 +/- 0.228, 2.52 +/- 0.525, and 3.54 +/- 1.12 for the iv, ip, and po data, respectively.",Pharmacokinetics of propafenone enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,2.52,102343,DB00908,Quinidine
,1981549,AUC ratio,"After all routes of administration, the AUC for the (-)-enantiomer was significantly higher than that of its antipode: the mean +/- SD values of (-):(+) AUC ratio were 1.99 +/- 0.228, 2.52 +/- 0.525, and 3.54 +/- 1.12 for the iv, ip, and po data, respectively.",Pharmacokinetics of propafenone enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,3.54,102344,DB00908,Quinidine
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.422,102345,DB00908,Quinidine
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.254,102346,DB00908,Quinidine
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.493,102347,DB00908,Quinidine
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.402,102348,DB00908,Quinidine
,15801548,"CLr,u/GFR ratio","In rhesus monkeys, renal elimination of compound A also involved tubular secretion, with a CLr,u/GFR ratio of about 30.",Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801548/),,30,103091,DB00908,Quinidine
,15801548,renal secretion,The renal secretion of compound A was not affected by either cimetidine (about 120 microM) or PAH (about 80 microM).,Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801548/),Î¼M,120,103092,DB00908,Quinidine
,15801548,Km,"In an uptake study using rOAT1 and rOAT3 transfected HEK cell lines, compound A was shown to be a substrate for rat OAT3 (Km= 15 microM), but not rat OAT1.",Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801548/),Î¼M,15,103093,DB00908,Quinidine
,3816879,tmax,Both oral forms of HDHQ were absorbed rapidly (tmax 1 h-1.2 h) with an absolute bioavailability of the oral solution (F = 0.54 to 0.93) which was not significantly different from that of the tablet (F = 0.66 to 0.90).,Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816879/),1/[h],1,103437,DB00908,Quinidine
,3816879,steady-state volume of distribution,HDHQ was rapidly and extensively distributed to the tissues with a high steady-state volume of distribution (6.82 +/- 1.85 l X kg-1).,Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816879/),[l] / [kg],6.82,103438,DB00908,Quinidine
,3816879,elimination half-life,"Mean elimination half-life was 6.7 +/- 1.4 h after IV infusion, 8.4 +/- 1.7 h after the oral solution and 11.3 +/- 4.4 h after the tablet administration.",Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816879/),h,6.7,103439,DB00908,Quinidine
,3816879,elimination half-life,"Mean elimination half-life was 6.7 +/- 1.4 h after IV infusion, 8.4 +/- 1.7 h after the oral solution and 11.3 +/- 4.4 h after the tablet administration.",Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816879/),h,8.4,103440,DB00908,Quinidine
,3816879,elimination half-life,"Mean elimination half-life was 6.7 +/- 1.4 h after IV infusion, 8.4 +/- 1.7 h after the oral solution and 11.3 +/- 4.4 h after the tablet administration.",Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816879/),h,11.3,103441,DB00908,Quinidine
,9627074,QT intervals,"Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 +/- 1.40 vs 56.60 +/- 0.748 msec, mean +/- SEM, p < 0.0001).",Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627074/),ms,65.90,104276,DB00908,Quinidine
,9627074,QT intervals,"Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 +/- 1.40 vs 56.60 +/- 0.748 msec, mean +/- SEM, p < 0.0001).",Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627074/),ms,56.60,104277,DB00908,Quinidine
,2625371,elimination half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,29.5,108152,DB00908,Quinidine
,2625371,clearance,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[ml] / [hÂ·kg],24,108153,DB00908,Quinidine
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,18.8,108154,DB00908,Quinidine
,2625371,half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,8.8,108155,DB00908,Quinidine
,2625371,half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,9.8,108156,DB00908,Quinidine
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,3.6,108157,DB00908,Quinidine
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,3.8,108158,DB00908,Quinidine
,2625371,apparent elimination half-life,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,12.8,108159,DB00908,Quinidine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[l] / [h],15.6,108160,DB00908,Quinidine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,9.9,108161,DB00908,Quinidine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[l] / [h],13.45,108162,DB00908,Quinidine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,10.3,108163,DB00908,Quinidine
,460341,clearance,The addition of quinidine decreased renal glycoside clearance (from 91.6 +/- 27.8 to 40.6 +/- 15.8 ml per minute) (P less than 0.001).,"Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/460341/),[ml] / [min],91.6,108504,DB00908,Quinidine
,460341,clearance,The addition of quinidine decreased renal glycoside clearance (from 91.6 +/- 27.8 to 40.6 +/- 15.8 ml per minute) (P less than 0.001).,"Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/460341/),[ml] / [min],40.6,108505,DB00908,Quinidine
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.40,109827,DB00908,Quinidine
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.33,109828,DB00908,Quinidine
,6702560,unbound quinidine fraction,"The unbound quinidine fraction was 6.3 +/- 2.8% in the survivors of prehospital cardiac arrest, a value significantly lower than normal individuals (unbound quinidine fraction = 9.9 +/- 3.0%, p less than 0.005).",Abnormal quinidine binding in survivors of prehospital cardiac arrest. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702560/),%,6.3,111044,DB00908,Quinidine
,6702560,unbound quinidine fraction,"The unbound quinidine fraction was 6.3 +/- 2.8% in the survivors of prehospital cardiac arrest, a value significantly lower than normal individuals (unbound quinidine fraction = 9.9 +/- 3.0%, p less than 0.005).",Abnormal quinidine binding in survivors of prehospital cardiac arrest. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702560/),%,9.9,111045,DB00908,Quinidine
,6702560,half-life,"The resultant quinidine interdose half-life was significantly prolonged (10 +/- 3 hours) when compared to normal (6 +/- 2 hours, p less than 0.02).",Abnormal quinidine binding in survivors of prehospital cardiac arrest. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702560/),h,10,111046,DB00908,Quinidine
,6702560,half-life,"The resultant quinidine interdose half-life was significantly prolonged (10 +/- 3 hours) when compared to normal (6 +/- 2 hours, p less than 0.02).",Abnormal quinidine binding in survivors of prehospital cardiac arrest. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702560/),h,6,111047,DB00908,Quinidine
,6702560,unbound quinidine fraction,The reduction in free drug fraction in cardiac arrest survivors was a nonspecific finding in that free drug fraction was also reduced in the patients with coronary artery disease (unbound quinidine fraction = 7.4 +/- 3%) and was independent of the alpha-1-glycoprotein concentration.,Abnormal quinidine binding in survivors of prehospital cardiac arrest. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702560/),%,7.4,111048,DB00908,Quinidine
,8706777,Free concentrations,"Free concentrations of quinidine were 11-times lower in cerebrospinal fluid than in plasma, and ranged from 9-15 nmol.l-1.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],9-15,112338,DB00908,Quinidine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],1.45,112339,DB00908,Quinidine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],9.86,112340,DB00908,Quinidine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],0.23,112341,DB00908,Quinidine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],3.63,112342,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,3.07 x 10 (,112343,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,1.68-3.68 x 10 (-3,112344,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,19.87 x 10 (-3),112345,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,9.87-66.22 x 10 (,112346,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),-3Â·10Â·d,0.83,112347,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,0.58-1.45 x 10 (,112348,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,7.19 x 10 (-3),112349,DB00908,Quinidine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,2.03-17.7 x 10 (-3,112350,DB00908,Quinidine
,7095920,peak concentration,"After a single dose of two tablets of dihydroquinidine chloride (300 mg), the average peak concentration was 0.74 +/- 0.43 mg/l (+/- SD); following administration two capsules of the sustained-release form (500 mg dihydroquinidine chloride) the average peak concentration was 0.55 +/- 0.25 mg/l.",The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),[mg] / [l],0.74,114359,DB00908,Quinidine
,7095920,peak concentration,"After a single dose of two tablets of dihydroquinidine chloride (300 mg), the average peak concentration was 0.74 +/- 0.43 mg/l (+/- SD); following administration two capsules of the sustained-release form (500 mg dihydroquinidine chloride) the average peak concentration was 0.55 +/- 0.25 mg/l.",The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),[mg] / [l],0.55,114360,DB00908,Quinidine
,7095920,Tmax,Tmax was approximately 5 h with the dihydroquinidine tablet and 7 h with the dihydroquinidine capsule.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),h,5,114361,DB00908,Quinidine
,7095920,Tmax,Tmax was approximately 5 h with the dihydroquinidine tablet and 7 h with the dihydroquinidine capsule.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),h,7,114362,DB00908,Quinidine
,7095920,absolute bioavailability,The mean absolute bioavailability was 89 +/- 9% for the conventional tablet and 52 +/- 15% for the sustained-release capsule.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),%,89,114363,DB00908,Quinidine
,7095920,absolute bioavailability,The mean absolute bioavailability was 89 +/- 9% for the conventional tablet and 52 +/- 15% for the sustained-release capsule.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),%,52,114364,DB00908,Quinidine
,7095920,volume of distribution (Vd),The volume of distribution (Vd) was 4.67 l/kg.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),[l] / [kg],4.67,114365,DB00908,Quinidine
,7095920,Distribution (t1/2 alpha,Distribution (t1/2 alpha = 18.63 +/- 15.2 h) and the apparent elimination half-life (t1/2 beta = 10.8 +/- 4.7 h) were longer than the corresponding values reported by Ueda et al. [1976].,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),h,18.63,114366,DB00908,Quinidine
,7095920,apparent elimination half-life (t1/2 beta,Distribution (t1/2 alpha = 18.63 +/- 15.2 h) and the apparent elimination half-life (t1/2 beta = 10.8 +/- 4.7 h) were longer than the corresponding values reported by Ueda et al. [1976].,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),h,10.8,114367,DB00908,Quinidine
,7095920,total body clearance (Cl),Mean total body clearance (Cl) was 0.28 +/- 0.057 l/h/kg.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),[l] / [hÂ·kg],0.28,114368,DB00908,Quinidine
,7095920,renal clearance (Clr),The renal clearance (Clr) was 0.062 +/- 0.018 l/h/kg.,The bioavailability and kinetics of dihydroquinidine in patients with heart disease. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7095920/),[l] / [hÂ·kg],0.062,114369,DB00908,Quinidine
,7283244,apparent volume of distribution,"The apparent volume of distribution of quinidine base was 3.10 +/- 0.79 L/kg, total body clearance was 5.49 +/- 2.40 ml/minute/kg, and plasma half-life was 6.65 +/- 3.00 hours.",Pharmacokinetic analysis of intravenously and orally administered quinidine in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283244/),[l] / [kg],3.10,117024,DB00908,Quinidine
,7283244,total body clearance,"The apparent volume of distribution of quinidine base was 3.10 +/- 0.79 L/kg, total body clearance was 5.49 +/- 2.40 ml/minute/kg, and plasma half-life was 6.65 +/- 3.00 hours.",Pharmacokinetic analysis of intravenously and orally administered quinidine in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283244/),[ml] / [kgÂ·min],5.49,117025,DB00908,Quinidine
,7283244,plasma half-life,"The apparent volume of distribution of quinidine base was 3.10 +/- 0.79 L/kg, total body clearance was 5.49 +/- 2.40 ml/minute/kg, and plasma half-life was 6.65 +/- 3.00 hours.",Pharmacokinetic analysis of intravenously and orally administered quinidine in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283244/),h,6.65,117026,DB00908,Quinidine
,7283244,systemic availability,The systemic availability of quinidine sulfate after oral administration of a 10 mg/kg dose was 48.5 +/- 20.4%.,Pharmacokinetic analysis of intravenously and orally administered quinidine in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283244/),%,48.5,117027,DB00908,Quinidine
,7283244,peak plasma concentrations,"Oral administrations of quinidine sulfate in doses of 10 mg/kg and 10 g produced peak plasma concentrations of 0.79 microgram/ml at 146 minutes and 1.47 microgram/ml at 131 minutes, respectively.",Pharmacokinetic analysis of intravenously and orally administered quinidine in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283244/),[Î¼g] / [ml],0.79,117028,DB00908,Quinidine
,7283244,peak plasma concentrations,"Oral administrations of quinidine sulfate in doses of 10 mg/kg and 10 g produced peak plasma concentrations of 0.79 microgram/ml at 146 minutes and 1.47 microgram/ml at 131 minutes, respectively.",Pharmacokinetic analysis of intravenously and orally administered quinidine in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283244/),[Î¼g] / [ml],1.47,117029,DB00908,Quinidine
,356577,elimination half-life (t 1/2 beta),"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),h,7.3,118945,DB00908,Quinidine
,356577,total volume of distribution (Vd),"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),[l] / [kg],2.39,118946,DB00908,Quinidine
,356577,total clearance,"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),[ml] / [kgÂ·min],4.04,118947,DB00908,Quinidine
,356577,renal clearance,"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),[ml] / [kgÂ·min],1.43,118948,DB00908,Quinidine
,356577,percent unbound,"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),,24.6,118949,DB00908,Quinidine
,356577,Vd,"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),[l] / [kg],2.18,118950,DB00908,Quinidine
,356577,percent unbound,"Mean kinetic values for total quinidine in the young subjects were: elimination half-life (t 1/2 beta), 7.3 hours; total volume of distribution (Vd), 2.39 liters/kg; total clearance, 4.04 ml/min per kg; renal clearance 1.43 ml/min per kg; and percent unbound, 24.6 In the elderly subjects, the values for Vd (2.18 liters/kg) and percent unbound (28.2) did not differ significantly from these values in the young subjects.",Reduced quinidine clearance in elderly persons. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),,28.2,118951,DB00908,Quinidine
,356577,t 1/2 beta,"However, in the elderly subjects t 1/2 beta was significantly longer (9.7 hours, P less than 0.05) and total quinidine clearance significantly less (2.64 ml/min per kg, P less than 0.005) than in the young subjects.",Reduced quinidine clearance in elderly persons. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),h,9.7,118952,DB00908,Quinidine
,356577,clearance,"However, in the elderly subjects t 1/2 beta was significantly longer (9.7 hours, P less than 0.05) and total quinidine clearance significantly less (2.64 ml/min per kg, P less than 0.005) than in the young subjects.",Reduced quinidine clearance in elderly persons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),[ml] / [kgÂ·min],2.64,118953,DB00908,Quinidine
,356577,Renal clearance,"Renal clearance of quinidine in the elderly was also significantly less (0.99 ml/min per kg, P less than 0.05) than in the young and was associated with lower rates of creatinine clearance in the elderly (r = 0.66).",Reduced quinidine clearance in elderly persons. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/356577/),[ml] / [kgÂ·min],0.99,118954,DB00908,Quinidine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],9.6,118977,DB00908,Quinidine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],3.1,118978,DB00908,Quinidine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],9.8,118979,DB00908,Quinidine
,1685525,clearance,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),[ml] / [min],3.5,118980,DB00908,Quinidine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,1198,118981,DB00908,Quinidine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,466,118982,DB00908,Quinidine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,1352,118983,DB00908,Quinidine
,1685525,volume of distribution,The higher concentration of AAG (2.0 g L-1) resulted in a significant decrease in clearance [quinine study (control: 9.6 +/- 2.9 vs test: 3.1 +/- 1.2 mL min-1); quinidine study (control: 9.8 +/- 2.4 vs test: 3.5 +/- 1.1 mL min-1]) and volume of distribution [quinine study (control: 1198 +/- 416 vs test: 466 +/- 95 mL); quinidine study (control: 1352 +/- 459 vs test: 317 +/- 24 mL]) but not the elimination half-life compared with control.,The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685525/),ml,317,118984,DB00908,Quinidine
,1234016,constant red cell/buffer partition ratio,A constant red cell/buffer partition ratio of 4.16+/-0.15 s.e. mean was found.,The distribution of quinidine in human blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1234016/),,4.16,119449,DB00908,Quinidine
,1234016,red cell/plasma partition ratio,3 Plasma reduced the uptake of quinidine so that a red cell/plasma partition ratio of 0.82+/-0.09 s.e. mean was found.,The distribution of quinidine in human blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1234016/),,0.82,119450,DB00908,Quinidine
,16019950,terminal elimination half-life,"Upon intravenous (IV) administration, the concentration of DRF 4367 declined in a bi-exponential fashion with a terminal elimination half-life of 4.0 h.","Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),h,4.0,122554,DB00908,Quinidine
,16019950,volume of distribution,"The volume of distribution and systemic clearance of DRF 4367 in mice were 0.80 l h(-1) kg(-1) and 0.14 l kg(-1), respectively, after IV administration.","Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),[l] / [hÂ·kg],0.80,122555,DB00908,Quinidine
,16019950,systemic clearance,"The volume of distribution and systemic clearance of DRF 4367 in mice were 0.80 l h(-1) kg(-1) and 0.14 l kg(-1), respectively, after IV administration.","Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),[l] / [kg],0.14,122556,DB00908,Quinidine
,16019950,absolute oral bioavailability,The absolute oral bioavailability of DRF 4367 was 44%.,"Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),%,44,122557,DB00908,Quinidine
,32014539,QA interval,QA interval decreased with nifedipine (30 Â± 1 versus 24 Â± 0 ms) and diltiazem (34 Â± 1 versus 27 Â± 1 ms) but increased with verapamil (30 Â± 0 versus 37 Â± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124537,DB00908,Quinidine
,32014539,QA interval,QA interval decreased with nifedipine (30 Â± 1 versus 24 Â± 0 ms) and diltiazem (34 Â± 1 versus 27 Â± 1 ms) but increased with verapamil (30 Â± 0 versus 37 Â± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,24,124538,DB00908,Quinidine
,32014539,QA interval,QA interval decreased with nifedipine (30 Â± 1 versus 24 Â± 0 ms) and diltiazem (34 Â± 1 versus 27 Â± 1 ms) but increased with verapamil (30 Â± 0 versus 37 Â± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,34,124539,DB00908,Quinidine
,32014539,QA interval,QA interval decreased with nifedipine (30 Â± 1 versus 24 Â± 0 ms) and diltiazem (34 Â± 1 versus 27 Â± 1 ms) but increased with verapamil (30 Â± 0 versus 37 Â± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,27,124540,DB00908,Quinidine
,32014539,QA interval,QA interval decreased with nifedipine (30 Â± 1 versus 24 Â± 0 ms) and diltiazem (34 Â± 1 versus 27 Â± 1 ms) but increased with verapamil (30 Â± 0 versus 37 Â± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124541,DB00908,Quinidine
,32014539,QA interval,QA interval decreased with nifedipine (30 Â± 1 versus 24 Â± 0 ms) and diltiazem (34 Â± 1 versus 27 Â± 1 ms) but increased with verapamil (30 Â± 0 versus 37 Â± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,37,124542,DB00908,Quinidine
,2719900,steady-state plasma,"3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%.",Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719900/),[ng] / [ml],408,126193,DB00908,Quinidine
,2719900,steady-state plasma,"3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%.",Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719900/),[ng] / [ml],1096,126194,DB00908,Quinidine
,6370540,oral bioavailability,Available evidence suggests that absorption of amiodarone following oral administration is erratic and unpredictable; oral bioavailability ranges from 22 to 86%.,Clinical pharmacokinetics of amiodarone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,22 to 86,128509,DB00908,Quinidine
,6370540,protein binding,In vitro protein binding of amiodarone has been reported to be 96.3 +/- 0.6%.,Clinical pharmacokinetics of amiodarone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,96.3,128510,DB00908,Quinidine
,6370540,plasma half-life,The plasma half-life of amiodarone after single-dose administration has been reported to be in the range of 3.2 to 79.7 hours.,Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,3.2 to 79.7,128511,DB00908,Quinidine
,6370540,half-life,"However, after withdrawal of long term amiodarone treatment the half-life is as long as 100 days.",Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),d,100,128512,DB00908,Quinidine
,6370540,Total body clearance,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [min],0.10 to 0.77,128513,DB00908,Quinidine
,6370540,apparent volume of distribution,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [kg],0.9 and 148,128514,DB00908,Quinidine
,6370540,time of onset of action,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),min,1 and 30,128515,DB00908,Quinidine
,6370540,duration of effect,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,1 and 3,128516,DB00908,Quinidine
,9758674,Km,"Formation of OH-DMI from DMI was consistent with Michaelis-Menten kinetics, having a mean Km value of 11.7 microM (range: 9.9-15.3 microM).",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),Î¼M,11.7,129119,DB00908,Quinidine
,9758674,inhibition constant,"Quinidine, a highly potent and relatively selective inhibitor of P450-2D6, strongly inhibited OH-DMI formation with an apparent competitive mechanism, having a mean inhibition constant of 0.16 microM (range: 0.13-0.18 microM).",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),Î¼M,0.16,129120,DB00908,Quinidine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),Î¼M,4.8,129121,DB00908,Quinidine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),Î¼M,15.6,129122,DB00908,Quinidine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),Î¼M,24.0,129123,DB00908,Quinidine
,9758674,inhibition constants,"Mean inhibition constants (small numbers indicating greater inhibiting potency) were as follows: ritonavir, 4.8 microM; indinavir, 15.6 microM; saquinavir, 24.0 microM; nelfinavir, 51.9 microM.",Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758674/),Î¼M,51.9,129124,DB00908,Quinidine
,15089813,t(max),"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,0.3,129487,DB00908,Quinidine
,15089813,t(max),"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,0.3,129488,DB00908,Quinidine
,15089813,peak,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,5.3,129489,DB00908,Quinidine
,15089813,peak,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,5.1,129490,DB00908,Quinidine
,15089813,AUC vs time,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),hÂ·mm,25.0,129491,DB00908,Quinidine
,15089813,AUC vs time,"Miosis t(max) (0.3 +/- 0.3 vs 0.3 +/- 0.2 h (-0.17, 0.22)), peak (5.3 +/- 0.8 vs 5.1 +/- 1.0 mm (0.39, 0.84)) and AUC vs time (25.0 +/- 5.7 vs 26.8 +/- 7.1 mm h (-6.1, 2.5)) were unchanged (placebo vs quinidine (95% confidence interval on the difference)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),hÂ·mm,26.8,129492,DB00908,Quinidine
,15089813,t(max),"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,2.4,129493,DB00908,Quinidine
,15089813,t(max),"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),h,1.6,129494,DB00908,Quinidine
,15089813,peak miosis,"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,3.2,129495,DB00908,Quinidine
,15089813,peak miosis,"Quinidine increased (P < 0.05) plasma methadone concentrations during the absorptive phase, decreased t(max) (2.4 +/- 0.7 vs 1.6 +/- 0.9 h (0.33, 1.2)), and increased peak miosis (3.2 +/- 1.5 vs 4.3 +/- 1.6 mm (-1.96, -0.19)) after oral methadone.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),mm,4.3,129496,DB00908,Quinidine
,15089813,C(max),"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[ng] / [ml],55.6,129497,DB00908,Quinidine
,15089813,C(max),"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[ng] / [ml],59.4,129498,DB00908,Quinidine
,15089813,AUC,"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[-54Â·hÂ·ng] / [ml],298,129499,DB00908,Quinidine
,15089813,AUC,"The C(max) (55.6 +/- 10.3 vs 59.4 +/- 14.1 ng ml(-1) (-8.5, 0.65)) and AUC of methadone (298 +/- 46 vs 316 +/- 74 ng ml(-1) h (-54, 18)) were unchanged, as were the EDDP : methadone AUC ratios.","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),[-54Â·hÂ·ng] / [ml],316,129500,DB00908,Quinidine
,15089813,rate constant,"Quinidine had no effect on the rate constant for transfer of methadone between plasma and effect compartment (k(e0)) (2.6 +/- 2.6 vs 2.5 +/- 1.4 h(-1) (-3.5, 4.2)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),1/[h],2.6,129501,DB00908,Quinidine
,15089813,rate constant,"Quinidine had no effect on the rate constant for transfer of methadone between plasma and effect compartment (k(e0)) (2.6 +/- 2.6 vs 2.5 +/- 1.4 h(-1) (-3.5, 4.2)).","The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089813/),1/[h],2.5,129502,DB00908,Quinidine
,10780263,oral clearance,"In extensive metabolizers, quinidine decreased venlafaxine oral clearance from 100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P < 0.05) without any effects on renal clearance (4 +/- 1 l/h during venlafaxine alone and 4 +/- 1 l/h during venlafaxine plus quinidine).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],100,130145,DB00908,Quinidine
,10780263,oral clearance,"In extensive metabolizers, quinidine decreased venlafaxine oral clearance from 100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P < 0.05) without any effects on renal clearance (4 +/- 1 l/h during venlafaxine alone and 4 +/- 1 l/h during venlafaxine plus quinidine).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],17,130146,DB00908,Quinidine
,10780263,renal clearance,"In extensive metabolizers, quinidine decreased venlafaxine oral clearance from 100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P < 0.05) without any effects on renal clearance (4 +/- 1 l/h during venlafaxine alone and 4 +/- 1 l/h during venlafaxine plus quinidine).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],4,130147,DB00908,Quinidine
,10780263,metabolic clearances,"In these individuals, the sequential metabolism of venlafaxine to O-desmethylvenlafaxine and to N,O-didesmethylvenlafaxine was inhibited by quinidine coadministration so that metabolic clearances to O-desmethylated metabolites decreased from 43 +/- 32 l/h to 2 +/- 1 l/h (P < 0.05).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],43,130148,DB00908,Quinidine
,10780263,metabolic clearances,"In these individuals, the sequential metabolism of venlafaxine to O-desmethylvenlafaxine and to N,O-didesmethylvenlafaxine was inhibited by quinidine coadministration so that metabolic clearances to O-desmethylated metabolites decreased from 43 +/- 32 l/h to 2 +/- 1 l/h (P < 0.05).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],2,130149,DB00908,Quinidine
,495420,half-life,"The mean half-life of quinidine was 4.5 hours, but there was wide individual variation.",Quinidine therapy in hospitalized patients with ventricular arrhythmias. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495420/),h,4.5,130820,DB00908,Quinidine
,495420,urinary excretion,The average urinary excretion of quinidine was only 11.3%.,Quinidine therapy in hospitalized patients with ventricular arrhythmias. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495420/),%,11.3,130821,DB00908,Quinidine
,20595378,apparent elimination rate constant (Î»(z)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0027,131299,DB00908,Quinidine
,20595378,clearance (CL_F),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[ml] / [min],131,131300,DB00908,Quinidine
,20595378,area under the curve (AUC(0-â)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[minÂ·Î¼g] / [ml],39,131301,DB00908,Quinidine
,20595378,area under the curve (AUC(0-â)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0058,131302,DB00908,Quinidine
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),min,435,131303,DB00908,Quinidine
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0058,131304,DB00908,Quinidine
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[ml] / [min],296,131305,DB00908,Quinidine
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (Î»(z)), 0.0027 Â± 0.0002 min(-1); clearance (CL_F), 131 Â± 21 ml/min; area under the curve (AUC(0-â)), 39 Â± 7.0 Î¼g Â· min/ml; and mean residence time, 435 Â± 20 min] were significantly different from those of the control (0.0058 Â± 0.0006 min(-1), 296 Â± 46 ml/min, 17 Â± 3 Î¼g Â· min/ml, and 232 Â± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),min,232,131306,DB00908,Quinidine
,9165569,half-life,The apparent quinidine half-life ranged from 66-99 hours and was associated with QT prolongation and persistent U waves.,Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165569/),h,66-99,131548,DB00908,Quinidine
,1559308,QUIN,"In the above, QUIN is 0.567 if quinidine is being concurrently administered and 1.0 if it is not.",Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559308/),,0.567,131956,DB00908,Quinidine
,1559308,QUIN,"In the above, QUIN is 0.567 if quinidine is being concurrently administered and 1.0 if it is not.",Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1559308/),,1.0,131957,DB00908,Quinidine
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.40,132812,DB00908,Quinidine
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.40,132813,DB00908,Quinidine
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.33,132814,DB00908,Quinidine
,18448569,AUC increase ratios,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1.7,132815,DB00908,Quinidine
,18448569,AUC increase ratios,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1.5,132816,DB00908,Quinidine
,18448569,f(m CYP2D6),"Moreover, the f(m CYP2D6) of R-125528 estimated to be almost 1 would well explain the accumulation of R-125528 observed with the quinidine treatment.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1,132817,DB00908,Quinidine
,17922078,Km,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),Î¼M,12.3,134955,DB00908,Quinidine
,17922078,Vmax,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),[nM] / [mgÂ·min],2.01,134956,DB00908,Quinidine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB00908,Quinidine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB00908,Quinidine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB00908,Quinidine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB00908,Quinidine
,3887162,Times,"Times required for parasite clearance and elimination of fever (49.4 +/- 17.8 and 69.5 +/- 18.7 hours, respectively) were comparable to those in earlier studies with a loading dose of quinine.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,49.4,136289,DB00908,Quinidine
,3887162,Times,"Times required for parasite clearance and elimination of fever (49.4 +/- 17.8 and 69.5 +/- 18.7 hours, respectively) were comparable to those in earlier studies with a loading dose of quinine.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,69.5,136290,DB00908,Quinidine
,3887162,elimination half-life,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,12.8,136291,DB00908,Quinidine
,3887162,volume of distribution,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[l] / [kg],1.68,136292,DB00908,Quinidine
,3887162,total clearance,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[ml] / [kgÂ·min],1.75,136293,DB00908,Quinidine
,3887162,urinary clearance,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[ml] / [kgÂ·min],0.62,136294,DB00908,Quinidine
,8369755,Hepatic extraction ratio (HER),"Hepatic extraction ratio (HER) of quinidine, which was determined at steady state blood concentrations from 0.5 to 2.3 micrograms/ml, was decreased from 0.8 to 0.35 with an increase in the quinidine concentration in control rats.",The influence of increased plasma protein binding on the disposition of quinidine in turpentine-treated rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369755/),[Î¼g] / [ml],0.8,138229,DB00908,Quinidine
,8369755,Hepatic extraction ratio (HER),"Hepatic extraction ratio (HER) of quinidine, which was determined at steady state blood concentrations from 0.5 to 2.3 micrograms/ml, was decreased from 0.8 to 0.35 with an increase in the quinidine concentration in control rats.",The influence of increased plasma protein binding on the disposition of quinidine in turpentine-treated rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369755/),[Î¼g] / [ml],0.35,138230,DB00908,Quinidine
,8369755,steady state blood concentrations,"Hepatic extraction ratio (HER) of quinidine, which was determined at steady state blood concentrations from 0.5 to 2.3 micrograms/ml, was decreased from 0.8 to 0.35 with an increase in the quinidine concentration in control rats.",The influence of increased plasma protein binding on the disposition of quinidine in turpentine-treated rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369755/),[Î¼g] / [ml],0.8,138231,DB00908,Quinidine
,8369755,steady state blood concentrations,"Hepatic extraction ratio (HER) of quinidine, which was determined at steady state blood concentrations from 0.5 to 2.3 micrograms/ml, was decreased from 0.8 to 0.35 with an increase in the quinidine concentration in control rats.",The influence of increased plasma protein binding on the disposition of quinidine in turpentine-treated rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369755/),[Î¼g] / [ml],0.35,138232,DB00908,Quinidine
,7197960,apparent elimination rate constant (k2,"Serum concentration curve, area under the serum concentration curve, peak serum quinidine levels (1.44 mg/l for both formulations), apparent elimination rate constant (k2 = 0.0882 and 0.0805 h-1, respectively) and elimination half-life show no significant differences.",[Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197960/),1/[h],0.0882,138531,DB00908,Quinidine
,7197960,apparent elimination rate constant (k2,"Serum concentration curve, area under the serum concentration curve, peak serum quinidine levels (1.44 mg/l for both formulations), apparent elimination rate constant (k2 = 0.0882 and 0.0805 h-1, respectively) and elimination half-life show no significant differences.",[Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197960/),1/[h],0.0805,138532,DB00908,Quinidine
,6880771,renal (,"From 3H-digoxin data quinidine was found to decrease both renal (from 1.19 +/- 0.35 to 0.86 +/- 0.21 ml/min./kg) (P less than 0.02) and extrarenal clearances of digoxin (from 0.85 +/- 0.24 to 0.49 +/- 0.23 ml/min./kg) (P less than 0.02), and to diminish the steady state distribution volume of the drug (from 6.78 +/- 1.23 to 5.63 +/- 1.64 l/kg) (P less than 0.02).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),[ml] / [Â·kgÂ·min],1.19,138582,DB00908,Quinidine
,6880771,renal (,"From 3H-digoxin data quinidine was found to decrease both renal (from 1.19 +/- 0.35 to 0.86 +/- 0.21 ml/min./kg) (P less than 0.02) and extrarenal clearances of digoxin (from 0.85 +/- 0.24 to 0.49 +/- 0.23 ml/min./kg) (P less than 0.02), and to diminish the steady state distribution volume of the drug (from 6.78 +/- 1.23 to 5.63 +/- 1.64 l/kg) (P less than 0.02).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),[ml] / [Â·kgÂ·min],0.86,138583,DB00908,Quinidine
,6880771,extrarenal clearances,"From 3H-digoxin data quinidine was found to decrease both renal (from 1.19 +/- 0.35 to 0.86 +/- 0.21 ml/min./kg) (P less than 0.02) and extrarenal clearances of digoxin (from 0.85 +/- 0.24 to 0.49 +/- 0.23 ml/min./kg) (P less than 0.02), and to diminish the steady state distribution volume of the drug (from 6.78 +/- 1.23 to 5.63 +/- 1.64 l/kg) (P less than 0.02).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),[ml] / [Â·kgÂ·min],0.85,138584,DB00908,Quinidine
,6880771,extrarenal clearances,"From 3H-digoxin data quinidine was found to decrease both renal (from 1.19 +/- 0.35 to 0.86 +/- 0.21 ml/min./kg) (P less than 0.02) and extrarenal clearances of digoxin (from 0.85 +/- 0.24 to 0.49 +/- 0.23 ml/min./kg) (P less than 0.02), and to diminish the steady state distribution volume of the drug (from 6.78 +/- 1.23 to 5.63 +/- 1.64 l/kg) (P less than 0.02).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),[ml] / [Â·kgÂ·min],0.49,138585,DB00908,Quinidine
,6880771,steady state distribution volume,"From 3H-digoxin data quinidine was found to decrease both renal (from 1.19 +/- 0.35 to 0.86 +/- 0.21 ml/min./kg) (P less than 0.02) and extrarenal clearances of digoxin (from 0.85 +/- 0.24 to 0.49 +/- 0.23 ml/min./kg) (P less than 0.02), and to diminish the steady state distribution volume of the drug (from 6.78 +/- 1.23 to 5.63 +/- 1.64 l/kg) (P less than 0.02).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),[l] / [kg],6.78,138586,DB00908,Quinidine
,6880771,steady state distribution volume,"From 3H-digoxin data quinidine was found to decrease both renal (from 1.19 +/- 0.35 to 0.86 +/- 0.21 ml/min./kg) (P less than 0.02) and extrarenal clearances of digoxin (from 0.85 +/- 0.24 to 0.49 +/- 0.23 ml/min./kg) (P less than 0.02), and to diminish the steady state distribution volume of the drug (from 6.78 +/- 1.23 to 5.63 +/- 1.64 l/kg) (P less than 0.02).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),[l] / [kg],5.63,138587,DB00908,Quinidine
,6880771,Plasma half-life,"Plasma half-life increased from 51.5 +/- 5.4 to 64.4 +/- 14.8 hrs (P less than 0.05), while urinary excretion half-life increased from 54.4 +/- 3.9 to 78.5 +/- 14.1 hrs (P less than 0.01).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),h,51.5,138588,DB00908,Quinidine
,6880771,Plasma half-life,"Plasma half-life increased from 51.5 +/- 5.4 to 64.4 +/- 14.8 hrs (P less than 0.05), while urinary excretion half-life increased from 54.4 +/- 3.9 to 78.5 +/- 14.1 hrs (P less than 0.01).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),h,64.4,138589,DB00908,Quinidine
,6880771,urinary excretion half-life,"Plasma half-life increased from 51.5 +/- 5.4 to 64.4 +/- 14.8 hrs (P less than 0.05), while urinary excretion half-life increased from 54.4 +/- 3.9 to 78.5 +/- 14.1 hrs (P less than 0.01).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),h,54.4,138590,DB00908,Quinidine
,6880771,urinary excretion half-life,"Plasma half-life increased from 51.5 +/- 5.4 to 64.4 +/- 14.8 hrs (P less than 0.05), while urinary excretion half-life increased from 54.4 +/- 3.9 to 78.5 +/- 14.1 hrs (P less than 0.01).",Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6880771/),h,78.5,138591,DB00908,Quinidine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],134,139399,DB00908,Quinidine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],87,139400,DB00908,Quinidine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],95,139401,DB00908,Quinidine
,2295215,steady-state biliary clearance,A marked reduction was found in the steady-state biliary clearance of digoxin from control value 134 +/- 57 ml/min (mean +/- SD) to 87 +/- 39 ml/min during treatment with quinine (p less than 0.05) and from 95 +/- 24 to 55 +/- 27 ml/min during treatment with quinidine (p less than 0.01; n = 4).,Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],55,139402,DB00908,Quinidine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],155,139403,DB00908,Quinidine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],110,139404,DB00908,Quinidine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],177,139405,DB00908,Quinidine
,2295215,renal clearance,"Quinidine reduced the renal clearance of digoxin (155 +/- 26 versus 110 +/- 21 ml/min) (p less than 0.05; n = 4), whereas quinine had no such effect (177 +/- 40 versus 185 +/- 53 ml/min; not significant).",Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295215/),[ml] / [min],185,139406,DB00908,Quinidine
,1793783,area under the time-plasma quinidine concentration curve,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[hÂ·Î¼g] / [ml],17.0,142357,DB00908,Quinidine
,1793783,area under the time-plasma quinidine concentration curve,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[hÂ·Î¼g] / [ml],18.6,142358,DB00908,Quinidine
,1793783,renal clearance,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[ml] / [min],56.2,142359,DB00908,Quinidine
,1793783,renal clearance,"During placebo and omeprazole treatment, there was no significant difference in area under the time-plasma quinidine concentration curve, (17.0 +/- 4.83 micrograms.h/ml, 18.6 +/- 4.43 micrograms.h/ml, respectively; P greater than 0.2) or renal clearance of quinidine (56.2 +/- 26.0 ml/min, 55.6 +/- 12.7 ml/min, respectively; P greater than 0.5).",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),[ml] / [min],55.6,142360,DB00908,Quinidine
,1793783,unbound fraction,Quinidine unbound fraction in plasma (0.170 +/- 0.041 vs. 0.166 +/- 0.041 in the presence of omeprazole; P greater than 0.5) was not altered by omeprazole.,Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),,0.170,142361,DB00908,Quinidine
,1793783,unbound fraction,Quinidine unbound fraction in plasma (0.170 +/- 0.041 vs. 0.166 +/- 0.041 in the presence of omeprazole; P greater than 0.5) was not altered by omeprazole.,Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),,0.166,142362,DB00908,Quinidine
,1793783,area under the time versus delta Q-Tc curve,"There was no significant difference in the change in the corrected Q-T interval on the electrocardiogram due to quinidine (mean area under the time versus delta Q-Tc curve = 351 +/- 192 ms.h, placebo; 414 +/- 303 ms.h, omeprazole) showing that quinidine pharmacodynamics were unaltered by omeprazole.",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),hÂ·ms,351,142363,DB00908,Quinidine
,1793783,area under the time versus delta Q-Tc curve,"There was no significant difference in the change in the corrected Q-T interval on the electrocardiogram due to quinidine (mean area under the time versus delta Q-Tc curve = 351 +/- 192 ms.h, placebo; 414 +/- 303 ms.h, omeprazole) showing that quinidine pharmacodynamics were unaltered by omeprazole.",Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1793783/),hÂ·ms,414,142364,DB00908,Quinidine
<,17851638,solubility,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),[Î¼g] / [ml],0.1,146683,DB00908,Quinidine
<,17851638,log Pe,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),,5.0,146684,DB00908,Quinidine
>,17851638,plasma protein binding,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),%,70,146685,DB00908,Quinidine
,8408733,area under the curve (AUC0-8),Nifedipine area under the curve (AUC0-8) increased 36.6% from 333 to 455 micrograms.hr/L (P < .05) after quinidine administration.,Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408733/),[hÂ·Î¼g] / [l],333,146746,DB00908,Quinidine
,8408733,area under the curve (AUC0-8),Nifedipine area under the curve (AUC0-8) increased 36.6% from 333 to 455 micrograms.hr/L (P < .05) after quinidine administration.,Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408733/),[hÂ·Î¼g] / [l],455,146747,DB00908,Quinidine
,15039292,clearance,"Using an alternative method, based on normalization of in vitro human data with the ratio of in vivo to in vitro animal data, the in vivo clearance in humans was predicted to be 0.39 l/h/kg.","Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039292/),[l] / [hÂ·kg],0.39,147080,DB00908,Quinidine
,456401,Plasma protein binding,"Plasma protein binding, expressed as the fraction of quinidine unbound ranged from 0.134--0.303 (mean 0.221).",Pharmacokinetics of quinidine related to plasma protein binding in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/456401/),,0.221,147289,DB00908,Quinidine
,456401,Elimination rate constant (beta),"Elimination rate constant (beta) varied from 0.071 to 0.146 h-1 (mean 0.113), and apparent volume of distribution (Vbeta) varied from 1.39--3.20 1 . kg-1 beta (mean 2.27).",Pharmacokinetics of quinidine related to plasma protein binding in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/456401/),1/[h],0.113,147290,DB00908,Quinidine
,456401,apparent volume of distribution (Vbeta),"Elimination rate constant (beta) varied from 0.071 to 0.146 h-1 (mean 0.113), and apparent volume of distribution (Vbeta) varied from 1.39--3.20 1 . kg-1 beta (mean 2.27).",Pharmacokinetics of quinidine related to plasma protein binding in man. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/456401/),beta,2.27,147291,DB00908,Quinidine
,456401,Total body clearance,Total body clearance was 2.32--6.49 ml min-1 .,Pharmacokinetics of quinidine related to plasma protein binding in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/456401/),[ml] / [min],2.32,147292,DB00908,Quinidine
,579055,total body clearance,In normal rats a total body clearance of 18.5 ml/min.,Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/579055/),[ml] / [min],18.5,147876,DB00908,Quinidine
,579055,renal clearance,and a renal clearance of 0.5 ml/min.,Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/579055/),[ml] / [min],0.5,147877,DB00908,Quinidine
,579055,blood flow,"The residual non-renal clearance (18.0 ml/min.), presumably taking place in the liver, exceeds the estimated liver blood flow (16.8 ml/min.), indicating efficient extraction of quinidine from plasma and blood cells (non-restrictive elimination).",Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/579055/),[ml] / [min],16.8,147878,DB00908,Quinidine
,579055,fraction of unbound quin,The fraction of unbound quinidine in serum was 30.6 +/- 0.6 (n = 23) and 16.7 +/- 0.5) (n = 23) percent in normal and anuric rats.,Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/579055/),%,30.6,147879,DB00908,Quinidine
,579055,fraction of unbound quin,The fraction of unbound quinidine in serum was 30.6 +/- 0.6 (n = 23) and 16.7 +/- 0.5) (n = 23) percent in normal and anuric rats.,Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/579055/),%,16.7,147880,DB00908,Quinidine
,12492607,apparent volume of distribution,"Accordingly, the free fraction of quinine was decreased (0.024 vs 0.063 [mean difference 0.0380; 95% CI 0.0221, 0.0539]) and the apparent volume of distribution tended to decrease (0.95 l kg-1 vs 1.43 l kg-1 [mean difference 0.480; 95% CI 0.193, 1.154]).",Quinine pharmacokinetics in chronic haemodialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[l] / [kg],0.95,149473,DB00908,Quinidine
,12492607,apparent volume of distribution,"Accordingly, the free fraction of quinine was decreased (0.024 vs 0.063 [mean difference 0.0380; 95% CI 0.0221, 0.0539]) and the apparent volume of distribution tended to decrease (0.95 l kg-1 vs 1.43 l kg-1 [mean difference 0.480; 95% CI 0.193, 1.154]).",Quinine pharmacokinetics in chronic haemodialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[l] / [kg],1.43,149474,DB00908,Quinidine
,12492607,clearance,"The clearance of free (unbound) quinine was increased in haemodialysis patients compared with controls (67.9 ml min-1 kg-1 vs 41.1 ml min-1 kg-1 [mean difference -26.8; 95% CI, -56.994, 3.469]), and the area under the curve (AUC) of the two main metabolites, 3-hydroxyquinine and 10,11-dihydroxydihydroquinine were increased.",Quinine pharmacokinetics in chronic haemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[ml] / [kgÂ·min],67.9,149475,DB00908,Quinidine
,12492607,clearance,"The clearance of free (unbound) quinine was increased in haemodialysis patients compared with controls (67.9 ml min-1 kg-1 vs 41.1 ml min-1 kg-1 [mean difference -26.8; 95% CI, -56.994, 3.469]), and the area under the curve (AUC) of the two main metabolites, 3-hydroxyquinine and 10,11-dihydroxydihydroquinine were increased.",Quinine pharmacokinetics in chronic haemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492607/),[ml] / [kgÂ·min],41.1,149476,DB00908,Quinidine
,7463324,terminal half-lives,"The terminal half-lives for quinidine and the metabolite were 132.4 +/- 27.1 and 65.4 +/- 34.4 min, respectively.",Comparative pharmacokinetics of quinidine and its O-desmethyl metabolite in rabbits. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463324/),min,132.4,153653,DB00908,Quinidine
,7463324,terminal half-lives,"The terminal half-lives for quinidine and the metabolite were 132.4 +/- 27.1 and 65.4 +/- 34.4 min, respectively.",Comparative pharmacokinetics of quinidine and its O-desmethyl metabolite in rabbits. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463324/),min,65.4,153654,DB00908,Quinidine
,26895496,terminal elimination half-life,"Following a single intravenous dose of antazoline mesylate (100 mg), the plasma concentration profile showed a relative fast elimination with a terminal elimination half-life of 2.29 h.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),h,2.29,154357,DB00908,Quinidine
,26895496,Vss,A relatively high volume of distribution was observed (Vss=315 L).,"Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),l,315,154358,DB00908,Quinidine
,26895496,mean residence time (MRTâ),"The values of mean residence time (MRTâ), area under the curve (AUCâ) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),h,3.45,154359,DB00908,Quinidine
,26895496,area under the curve (AUCâ),"The values of mean residence time (MRTâ), area under the curve (AUCâ) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),[hÂ·mg] / [l],0.91,154360,DB00908,Quinidine
,26895496,area under the curve (AUCâ),"The values of mean residence time (MRTâ), area under the curve (AUCâ) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),[l] / [h],80.5,154361,DB00908,Quinidine
,26895496,clearance,"The values of mean residence time (MRTâ), area under the curve (AUCâ) and clearance were 3.45 h, 0.91 mg h L(-1) and 80.5 L h(-1), respectively.","Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] human pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895496/),[l] / [h],80.5,154362,DB00908,Quinidine
,2357863,area under the plasma concentration-time curve,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[hÂ·ng] / [ml],530,157270,DB00908,Quinidine
,2357863,area under the plasma concentration-time curve,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[hÂ·ng] / [ml],1051,157271,DB00908,Quinidine
,2357863,clearance,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],3087,157272,DB00908,Quinidine
,2357863,clearance,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],1378,157273,DB00908,Quinidine
,2357863,partial metabolic clearance,"The metabolism of propranolol by the 4-hydroxylation pathway was almost abolished by quinidine, resulting in a fall in the partial metabolic clearance by this pathway from 678 +/- 246 to 56 +/- 11 ml/min (p less than 0.05).",Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],678,157274,DB00908,Quinidine
,2357863,partial metabolic clearance,"The metabolism of propranolol by the 4-hydroxylation pathway was almost abolished by quinidine, resulting in a fall in the partial metabolic clearance by this pathway from 678 +/- 246 to 56 +/- 11 ml/min (p less than 0.05).",Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],56,157275,DB00908,Quinidine
,14663457,maximum plasma concentration,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),[ng] / [ml],31.8,157589,DB00908,Quinidine
,14663457,maximum plasma concentration,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),[ng] / [ml],16.9,157590,DB00908,Quinidine
,14663457,AUC,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),ng,65.1,157591,DB00908,Quinidine
,14663457,AUC,"Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),ng,40.8,157592,DB00908,Quinidine
,14663457,AUC,"Differences in oral morphine miosis (AUC, 16.8 +/- 9.3 mm.",Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663457/),mm,16.8,157593,DB00908,Quinidine
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB00908,Quinidine
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB00908,Quinidine
,7325456,apparent volume of distribution,The apparent volume of distribution was 3.80 +/- 2.21 L/kg.,Pharmacokinetic analysis of intravenously and orally administered quinidine in cows. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325456/),[l] / [kg],3.80,159744,DB00908,Quinidine
,7325456,Total body clearance,Total body clearance was 19.0 +/- 7.02 ml/min/kg and plasma half-life was 2.25 +/- 0.68 hours.,Pharmacokinetic analysis of intravenously and orally administered quinidine in cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325456/),[ml] / [kgÂ·min],19.0,159745,DB00908,Quinidine
,7325456,plasma half-life,Total body clearance was 19.0 +/- 7.02 ml/min/kg and plasma half-life was 2.25 +/- 0.68 hours.,Pharmacokinetic analysis of intravenously and orally administered quinidine in cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325456/),h,2.25,159746,DB00908,Quinidine
,7325456,systemic availability,The systemic availability of quinidine sulfate after oral administration of a 20 mg/kg dose was 23.3 +/- 16.3%.,Pharmacokinetic analysis of intravenously and orally administered quinidine in cows. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325456/),%,23.3,159747,DB00908,Quinidine
,7325456,peak plasma concentration,The mean peak plasma concentration reached in 7 cows after oral administration of quinidine sulfate was 0.26 micrograms/ml.,Pharmacokinetic analysis of intravenously and orally administered quinidine in cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325456/),[Î¼g] / [ml],0.26,159748,DB00908,Quinidine
,22764568,recovered amounts,The recovered amounts of quinidine 30 min after administration were 21.1% of dose in control rats and 94.7% in ranitidine-treated rats.,"Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764568/),%,21.1,162642,DB00908,Quinidine
,22764568,recovered amounts,The recovered amounts of quinidine 30 min after administration were 21.1% of dose in control rats and 94.7% in ranitidine-treated rats.,"Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764568/),%,94.7,162643,DB00908,Quinidine
,7241357,terminal rate constants,"The terminal rate constants, expressed as t 1/2, of the 24 subjects gave an overall mean of 7.49 +/- 0.77 hr and ranged from 6.24 +/- 0.28 to 0.49 +/- 0.90 hr in individuals.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),h,7.49,164922,DB00908,Quinidine
,7241357,terminal rate constants,"The terminal rate constants, expressed as t 1/2, of the 24 subjects gave an overall mean of 7.49 +/- 0.77 hr and ranged from 6.24 +/- 0.28 to 0.49 +/- 0.90 hr in individuals.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),h,6.24,164923,DB00908,Quinidine
,7241357,terminal rate constants,"The terminal rate constants, expressed as t 1/2, of the 24 subjects gave an overall mean of 7.49 +/- 0.77 hr and ranged from 6.24 +/- 0.28 to 0.49 +/- 0.90 hr in individuals.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),h,0.49,164924,DB00908,Quinidine
,7241357,t 1/2,"The terminal rate constants, expressed as t 1/2, of the 24 subjects gave an overall mean of 7.49 +/- 0.77 hr and ranged from 6.24 +/- 0.28 to 0.49 +/- 0.90 hr in individuals.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),h,7.49,164925,DB00908,Quinidine
,7241357,t 1/2,"The terminal rate constants, expressed as t 1/2, of the 24 subjects gave an overall mean of 7.49 +/- 0.77 hr and ranged from 6.24 +/- 0.28 to 0.49 +/- 0.90 hr in individuals.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),h,6.24,164926,DB00908,Quinidine
,7241357,t 1/2,"The terminal rate constants, expressed as t 1/2, of the 24 subjects gave an overall mean of 7.49 +/- 0.77 hr and ranged from 6.24 +/- 0.28 to 0.49 +/- 0.90 hr in individuals.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),h,0.49,164927,DB00908,Quinidine
,7241357,total body clearance,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],70,164928,DB00908,Quinidine
,7241357,total body clearance,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],4.22,164929,DB00908,Quinidine
,7241357,total body clearance,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],2.49,164930,DB00908,Quinidine
,7241357,total body clearance,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],6.42,164931,DB00908,Quinidine
,7241357,oral bioavailability,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],70,164932,DB00908,Quinidine
,7241357,oral bioavailability,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],4.22,164933,DB00908,Quinidine
,7241357,oral bioavailability,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],2.49,164934,DB00908,Quinidine
,7241357,oral bioavailability,"The estimated total body clearance, with the assumption that the oral bioavailability was 70%, gave an overall mean of 4.22 +/- 1.05 and ranged from 2.49 +/- 0.28 to 6.42 +/- 0.70 mg/min/kg in individuals, demonstrating the wide range of quinidine disposition even in healthy subjects; this finding is in agreement with recently published results.",Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7241357/),[mg] / [kgÂ·min],6.42,164935,DB00908,Quinidine
,3220613,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- s.e.m.) by 33% from 23.7 +/- 2.5 to 15.9 +/- 1.7 l/h (p less than 0.05).,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[l] / [h],23.7,165148,DB00908,Quinidine
,3220613,apparent oral clearance,Cimetidine reduced the mean apparent oral clearance of quinidine (+/- s.e.m.) by 33% from 23.7 +/- 2.5 to 15.9 +/- 1.7 l/h (p less than 0.05).,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[l] / [h],15.9,165149,DB00908,Quinidine
,3220613,renal clearance,This 33% decline in oral clearance paralleled the 33% decline in renal clearance of unchanged quinidine which decreased from 56.7 +/- 13.3 to 38.3 +/- 3.3 ml/min.,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[ml] / [min],56.7,165150,DB00908,Quinidine
,3220613,renal clearance,This 33% decline in oral clearance paralleled the 33% decline in renal clearance of unchanged quinidine which decreased from 56.7 +/- 13.3 to 38.3 +/- 3.3 ml/min.,Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220613/),[ml] / [min],38.3,165151,DB00908,Quinidine
,17431033,K(m),The K(m) value for the formation of M1 was 23.8 microM in human liver microsomes.,Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),Î¼M,23.8,166307,DB00908,Quinidine
,17431033,K(i),"The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),Î¼M,0.08,166308,DB00908,Quinidine
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,3,166309,DB00908,Quinidine
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,2 to 5,166310,DB00908,Quinidine
,10492795,clearance,"The estimated median (range) quinine clearance was 0.83 mL/kg/min (0.58-1.16), and 3OHQn clearance/fraction of quinine converted was 3.40 mL/kg/min (2.58-4.47).",Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492795/),[ml] / [kgÂ·min],0.83,166473,DB00908,Quinidine
,10492795,clearance/fraction of quinine converted,"The estimated median (range) quinine clearance was 0.83 mL/kg/min (0.58-1.16), and 3OHQn clearance/fraction of quinine converted was 3.40 mL/kg/min (2.58-4.47).",Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492795/),[ml] / [kgÂ·min],3.40,166474,DB00908,Quinidine
,10492795,terminal elimination half-life,The estimated 3OHQn terminal elimination half-life was 21 h (16.5-32.5).,Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492795/),h,21,166475,DB00908,Quinidine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,12.0,166574,DB00908,Quinidine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,3.5,166575,DB00908,Quinidine
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB00908,Quinidine
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB00908,Quinidine
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB00908,Quinidine
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB00908,Quinidine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB00908,Quinidine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB00908,Quinidine
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB00908,Quinidine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB00908,Quinidine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB00908,Quinidine
,8097780,hepatic perfusate rate,"When administered as separate 1 mg doses, the hepatic clearances of quinine and quinidine were similar to the hepatic perfusate rate of 10 mL min-1.",Quinine impairs quinidine clearance in rat perfused liver. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],10,169880,DB00908,Quinidine
,8097780,hepatic clearance,"When 1 mg of each was administered simultaneously, mean hepatic clearance of quinine was unchanged (9.00 +/- 2.20 mL min-1 separate dosage, n = 7; 6.87 +/- 1.77 mL min-1 simultaneous dosage, n = 7; P > 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],9.00,169881,DB00908,Quinidine
,8097780,hepatic clearance,"When 1 mg of each was administered simultaneously, mean hepatic clearance of quinine was unchanged (9.00 +/- 2.20 mL min-1 separate dosage, n = 7; 6.87 +/- 1.77 mL min-1 simultaneous dosage, n = 7; P > 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],6.87,169882,DB00908,Quinidine
,8097780,hepatic clearance,"By contrast, mean hepatic clearance of quinidine was reduced significantly by concomitant quinine (10.6 +/- 1.72 mL min-1 separate dosage, n = 7; 4.82 +/- 1.25 mL min-1 simultaneous dosage, n = 7; P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],10.6,169883,DB00908,Quinidine
,8097780,hepatic clearance,"By contrast, mean hepatic clearance of quinidine was reduced significantly by concomitant quinine (10.6 +/- 1.72 mL min-1 separate dosage, n = 7; 4.82 +/- 1.25 mL min-1 simultaneous dosage, n = 7; P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),[ml] / [min],4.82,169884,DB00908,Quinidine
,8097780,volumes of distribution,"There was no significant difference in volumes of distribution when each alkaloid was administered separately (131 +/- 46 mL quinine, 129 +/- 21 mL quinidine; P > 0.05) but concomitant quinine administration increased quinidine volume of distribution to 169 +/- 30 mL (P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),ml,131,169885,DB00908,Quinidine
,8097780,volumes of distribution,"There was no significant difference in volumes of distribution when each alkaloid was administered separately (131 +/- 46 mL quinine, 129 +/- 21 mL quinidine; P > 0.05) but concomitant quinine administration increased quinidine volume of distribution to 169 +/- 30 mL (P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),ml,129,169886,DB00908,Quinidine
,8097780,volume of distribution,"There was no significant difference in volumes of distribution when each alkaloid was administered separately (131 +/- 46 mL quinine, 129 +/- 21 mL quinidine; P > 0.05) but concomitant quinine administration increased quinidine volume of distribution to 169 +/- 30 mL (P < 0.05).",Quinine impairs quinidine clearance in rat perfused liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097780/),ml,169,169887,DB00908,Quinidine
,25406952,AUC,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[hÂ·mg] / [l],27.93,170438,DB00908,Quinidine
,25406952,AUC,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[hÂ·mg] / [l],41.62,170439,DB00908,Quinidine
,25406952,Cmax,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[mg] / [l],1.37,170440,DB00908,Quinidine
,25406952,Cmax,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[mg] / [l],1.64,170441,DB00908,Quinidine
,25406952,T1/2b,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),h,16.28,170442,DB00908,Quinidine
,25406952,T1/2b,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),h,21.43,170443,DB00908,Quinidine
,25406952,oral plasma clearance,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[l] / [h],23.17,170444,DB00908,Quinidine
,25406952,oral plasma clearance,"Administration of quinine plus ciprofloxacin resulted in significant increases (P < 0.05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27.93 Â± 8.04 vs. 41.62 Â± 13.98 hÂ·mg/L; Cmax: 1.37 Â± 0.24 vs. 1.64 Â± 0.38 mg/L; T1/2b: 16.28 Â± 2.66 vs. 21.43 Â± 3.22 hours), whereas the oral plasma clearance markedly decreased (23.17 Â± 6.49 vs. 16.00 Â± 5.27 L/h).",Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406952/),[l] / [h],16.00,170445,DB00908,Quinidine
,7213522,half-time,The equilibration between plasma and effect site had a half-time of 8 min.,The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213522/),min,8,171625,DB00908,Quinidine
,7213522,slope,The slope of the pharmacodynamic model was 20.3 ms . mg 1(-1) after i.v. dosing and 33.5 ms . mg 1(-1) after oral dosing.,The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213522/),mgÂ·ms,20.3,171626,DB00908,Quinidine
,7213522,slope,The slope of the pharmacodynamic model was 20.3 ms . mg 1(-1) after i.v. dosing and 33.5 ms . mg 1(-1) after oral dosing.,The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7213522/),mgÂ·ms,33.5,171627,DB00908,Quinidine
,14973303,area under the curve (AUC),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),hÂ·mm,13.6,172187,DB00908,Quinidine
,14973303,area under the curve (AUC),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),hÂ·mm,8.7,172188,DB00908,Quinidine
,14973303,k(el),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],0.35,172189,DB00908,Quinidine
,14973303,k(el),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],0.52,172190,DB00908,Quinidine
,14973303,plasma C(max),Quinidine increased oral fentanyl plasma C(max) (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs.,Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),[ng] / [ml],0.55,172191,DB00908,Quinidine
,14973303,plasma C(max),Quinidine increased oral fentanyl plasma C(max) (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs.,Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),[ng] / [ml],0.21,172192,DB00908,Quinidine
,14973303,AUC,Quinidine increased oral fentanyl plasma C(max) (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs.,Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),,1.9,172193,DB00908,Quinidine
,14973303,maximum miosis,"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),mm,3.4,172194,DB00908,Quinidine
,14973303,maximum miosis,"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),mm,2.3,172195,DB00908,Quinidine
,14973303,rate constant for the transfer between plasma and effect compartment (k(e0)),"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],1.9,172196,DB00908,Quinidine
,14973303,rate constant for the transfer between plasma and effect compartment (k(e0)),"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],3.6,172197,DB00908,Quinidine
,3512148,plasma concentrations,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[ng] / [ml],13.6,178053,DB00908,Quinidine
,3512148,plasma concentrations,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[ng] / [ml],19.7,178054,DB00908,Quinidine
,3512148,renal excretion,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[Î¼g] / [24Â·h],16.1,178055,DB00908,Quinidine
,3512148,renal excretion,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[Î¼g] / [24Â·h],23.4,178056,DB00908,Quinidine
,3512148,elimination t1/2,The elimination t1/2 was prolonged from 150.3 +/- 20.6 to 202.6 +/- 37.5 hours.,Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),h,150.3,178057,DB00908,Quinidine
,3512148,elimination t1/2,The elimination t1/2 was prolonged from 150.3 +/- 20.6 to 202.6 +/- 37.5 hours.,Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),h,202.6,178058,DB00908,Quinidine
,6532805,Vdss,"The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min.","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),[l] / [kg],4.78,178189,DB00908,Quinidine
,6532805,clearance,"The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min.","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),[l] / [min],0.074,178190,DB00908,Quinidine
,6532805,terminal half-life,"The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min.","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),min,720,178191,DB00908,Quinidine
,6532805,Vdss,"The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min.","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),[l] / [kg],1.03,178192,DB00908,Quinidine
,6532805,clearance,"The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min.","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),[l] / [min],0.065,178193,DB00908,Quinidine
,6532805,terminal half-life,"The compartment-independent pharmacokinetic parameters (mean +/- SD) were for quinidine Vdss 4.78 +/- 1.11 l/kg, clearance 0.074 +/- 0.047 l/min, terminal half-life 720 +/- 343 min and for quinidine-N-oxide Vdss 1.03 +/- 0.21 l/kg, clearance 0.065 +/- 0.012 l/min, terminal half-life 316 +/- 69 min.","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),min,316,178194,DB00908,Quinidine
,6532805,"Michaelis-Menten constant, KM","Non-linear renal elimination of the N-oxide was observed in two out of three dogs with a Michaelis-Menten constant, KM of about 7 micrograms/ml (21 microM).","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),[Î¼g] / [ml],7,178195,DB00908,Quinidine
,6532805,"Michaelis-Menten constant, KM","Non-linear renal elimination of the N-oxide was observed in two out of three dogs with a Michaelis-Menten constant, KM of about 7 micrograms/ml (21 microM).","Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6532805/),Î¼M,21,178196,DB00908,Quinidine
,12895193,Maximum quinidine concentrations,"Maximum quinidine concentrations in males and females were 997 +/- 56 and 871 +/- 57 ng ml(-1), respectively (mean difference (-125, 95% confidence intervals (CI) -239, 11 ng ml(-1), P = NS).",Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895193/),[ng] / [ml],997,180631,DB00908,Quinidine
,12895193,Maximum quinidine concentrations,"Maximum quinidine concentrations in males and females were 997 +/- 56 and 871 +/- 57 ng ml(-1), respectively (mean difference (-125, 95% confidence intervals (CI) -239, 11 ng ml(-1), P = NS).",Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895193/),[ng] / [ml],871,180632,DB00908,Quinidine
,11258173,absolute bioavailability,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),%,90,180720,DB00908,Quinidine
,11258173,elimination half-life,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),h,12,180721,DB00908,Quinidine
,263396,half-life,Patients with cirrhosis had a significantly longer quinidine half-life (9 +/- 1 hr; p less than .01) when compared to control patients (6 +/- 0.5h).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),h,9,181398,DB00908,Quinidine
,263396,half-life,Patients with cirrhosis had a significantly longer quinidine half-life (9 +/- 1 hr; p less than .01) when compared to control patients (6 +/- 0.5h).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),h,6,181399,DB00908,Quinidine
,263396,volume of distribution,This was not related to a reduced quinidine clearance rate but rather to an increase in quinidine volume of distribution (4.1 +/- .4 L./Kg. in cirrhotic patients vs 2.6 +/- 1 L./Kg. in control patients; p less than .01).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[l] / [kg],4.1,181400,DB00908,Quinidine
,263396,volume of distribution,This was not related to a reduced quinidine clearance rate but rather to an increase in quinidine volume of distribution (4.1 +/- .4 L./Kg. in cirrhotic patients vs 2.6 +/- 1 L./Kg. in control patients; p less than .01).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[l] / [kg],2.6,181401,DB00908,Quinidine
greater,263396,unbound fraction,Abnormal quinidine binding (greater than 25 per cent unbound fraction) was noted in seven of the eight cirrhotic patients.,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),%,25,181402,DB00908,Quinidine
,263396,half-life,"In contrast, patients receiving propranolol had a normal quinidine half-life of 6 +/- 0.5 hr.",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),h,6,181403,DB00908,Quinidine
,263396,clearance,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[ml] / [Â·kgÂ·min],3.3,181404,DB00908,Quinidine
,263396,clearance,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[ml] / [Â·kgÂ·min],5.3,181405,DB00908,Quinidine
,263396,peak concentrations,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[Î¼g] / [ml],1.25,181406,DB00908,Quinidine
,263396,peak concentrations,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[Î¼g] / [ml],.80,181407,DB00908,Quinidine
,15175422,Rate of elimination (k(10)),"Rate of elimination (k(10)) for erythromycin and those with inhibitors was found to be similar (141 +/- 23 min), suggesting that elimination pathways were not altered.",Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175422/),min,141,181611,DB00908,Quinidine
,12593761,biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kgÂ·min],1.186,183706,DB00908,Quinidine
,12593761,biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kgÂ·min],5.621,183707,DB00908,Quinidine
,12593761,intrinsic biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kgÂ·min],40.33,183708,DB00908,Quinidine
,12593761,intrinsic biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kgÂ·min],69.83,183709,DB00908,Quinidine
,7068936,extent of absorption,The extent of absorption of quinidine from the new marketed product was only 50 per cent of the innovator's product.,Serious bioavailability problems with a generic prolonged-release quinidine gluconate product. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068936/),%,50,187144,DB00908,Quinidine
,2741797,effective refractory period,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),,266,189266,DB00908,Quinidine
,2741797,effective refractory period,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),,279,189267,DB00908,Quinidine
,2741797,free fatty acid concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[mM] / [l],515,189268,DB00908,Quinidine
,2741797,free fatty acid concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[mM] / [l],1071,189269,DB00908,Quinidine
,2741797,unbound quinidine concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[Î¼g] / [ml],0.3,189270,DB00908,Quinidine
,2741797,unbound quinidine concentration,"Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration.",The clinical implication of changing unbound quinidine levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),[Î¼g] / [ml],0.,189271,DB00908,Quinidine
,2741797,half-life,"Eleven patients studied on day 3 (+/- 1) and day 10 (+/- 3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 +/- 4% versus 9 +/- 4%; p less than 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 +/- 2.7 versus 6.3 +/- 2.1 hours; p less than 0.02).",The clinical implication of changing unbound quinidine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),h,7.1,189272,DB00908,Quinidine
,2741797,half-life,"Eleven patients studied on day 3 (+/- 1) and day 10 (+/- 3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 +/- 4% versus 9 +/- 4%; p less than 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 +/- 2.7 versus 6.3 +/- 2.1 hours; p less than 0.02).",The clinical implication of changing unbound quinidine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741797/),h,6.3,189273,DB00908,Quinidine
,4087170,steady-state volume of distribution (Vss),The steady-state volume of distribution (Vss) determined over the plasma concentration range from 0.5 to 10 micrograms/ml was 6.0 +/- 0.45 L/kg.,Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087170/),[l] / [kg],6.0,189758,DB00908,Quinidine
,21508180,concentrations,"Throughout the study (follow-up, 199 Â± 155 days), quinidine successfully inhibited CYP2D6: propafenone concentrations were 3 times higher in patients receiving quinidine (1033 Â± 611 ng/mL vs 328 Â± 229 ng/mL; P < .001).",Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508180/),ng,103,191444,DB00908,Quinidine
,21508180,concentrations,"Throughout the study (follow-up, 199 Â± 155 days), quinidine successfully inhibited CYP2D6: propafenone concentrations were 3 times higher in patients receiving quinidine (1033 Â± 611 ng/mL vs 328 Â± 229 ng/mL; P < .001).",Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508180/),[ng] / [ml],328,191445,DB00908,Quinidine
,1611804,plasma concentrations,"The same dose of dextromethorphan in the presence of 75 mg quinidine every 12 hours resulted in dextromethorphan plasma concentrations of 241 +/- 94 ng/ml (range, 157 to 402 ng/ml; n = 5).",Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611804/),[ng] / [ml],241,192012,DB00908,Quinidine
,8889039,plasma concentrations (C10),"The plasma concentrations (C10), where 10 ms of QT prolongation was observed, were 1.03 microM for TFN and 5.12 microM for QND, respectively.",Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889039/),Î¼M,1.03,192518,DB00908,Quinidine
,8889039,plasma concentrations (C10),"The plasma concentrations (C10), where 10 ms of QT prolongation was observed, were 1.03 microM for TFN and 5.12 microM for QND, respectively.",Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889039/),Î¼M,5.12,192519,DB00908,Quinidine
,8889039,plasma unbound concentration of C10 (C10-f),"The calculated plasma unbound concentration of C10 (C10-f) was 10.3 nM for TFN and 3.82 microM for QND, which coincides with previously reported in vitro values of IC50 for potassium channels.",Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889039/),nM,10.3,192520,DB00908,Quinidine
,8889039,plasma unbound concentration of C10 (C10-f),"The calculated plasma unbound concentration of C10 (C10-f) was 10.3 nM for TFN and 3.82 microM for QND, which coincides with previously reported in vitro values of IC50 for potassium channels.",Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8889039/),Î¼M,3.82,192521,DB00908,Quinidine
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kgÂ·min],9.1,192659,DB00908,Quinidine
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kgÂ·min],7.6,192660,DB00908,Quinidine
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,9.6,192661,DB00908,Quinidine
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,11.5,192662,DB00908,Quinidine
,6747817,Plasma trough levels,"Plasma trough levels after 12 oral doses of quinidine sulfate every 4 hr averaged: quinidine, 2.89 +/- 0.50 mg/L; 3-hydroxy quinidine, 0.83 +/- 0.36 mg/L; quinidine N-oxide, 0.40 +/- 0.13 mg/L; and quinidine 10,11-dihydrodiol, 0.38 +/- 0.08 mg/L.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[mg] / [l],2.89,193062,DB00908,Quinidine
,6747817,Plasma trough levels,"Plasma trough levels after 12 oral doses of quinidine sulfate every 4 hr averaged: quinidine, 2.89 +/- 0.50 mg/L; 3-hydroxy quinidine, 0.83 +/- 0.36 mg/L; quinidine N-oxide, 0.40 +/- 0.13 mg/L; and quinidine 10,11-dihydrodiol, 0.38 +/- 0.08 mg/L.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[mg] / [l],0.83,193063,DB00908,Quinidine
,6747817,Plasma trough levels,"Plasma trough levels after 12 oral doses of quinidine sulfate every 4 hr averaged: quinidine, 2.89 +/- 0.50 mg/L; 3-hydroxy quinidine, 0.83 +/- 0.36 mg/L; quinidine N-oxide, 0.40 +/- 0.13 mg/L; and quinidine 10,11-dihydrodiol, 0.38 +/- 0.08 mg/L.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[mg] / [l],0.40,193064,DB00908,Quinidine
,6747817,Plasma trough levels,"Plasma trough levels after 12 oral doses of quinidine sulfate every 4 hr averaged: quinidine, 2.89 +/- 0.50 mg/L; 3-hydroxy quinidine, 0.83 +/- 0.36 mg/L; quinidine N-oxide, 0.40 +/- 0.13 mg/L; and quinidine 10,11-dihydrodiol, 0.38 +/- 0.08 mg/L.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[mg] / [l],0.38,193065,DB00908,Quinidine
,6747817,Vl,"Mean (+/- SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: Vl, 0.37 +/- 0.09 L/kg; lambda 1, 0.094 +/- 0.009 min-1; lambda 2, 0.0015 +/- 0.0002 min-1; EX2, 0.013 +/- 0.002 min-1; clearance (ClQ), 3.86 +/- 0.83 ml/min/kg.",Pharmacokinetics of quinidine and three of its metabolites in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[l] / [kg],0.37,193066,DB00908,Quinidine
,6747817,lambda 1,"Mean (+/- SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: Vl, 0.37 +/- 0.09 L/kg; lambda 1, 0.094 +/- 0.009 min-1; lambda 2, 0.0015 +/- 0.0002 min-1; EX2, 0.013 +/- 0.002 min-1; clearance (ClQ), 3.86 +/- 0.83 ml/min/kg.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.094,193067,DB00908,Quinidine
,6747817,lambda 2,"Mean (+/- SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: Vl, 0.37 +/- 0.09 L/kg; lambda 1, 0.094 +/- 0.009 min-1; lambda 2, 0.0015 +/- 0.0002 min-1; EX2, 0.013 +/- 0.002 min-1; clearance (ClQ), 3.86 +/- 0.83 ml/min/kg.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.0015,193068,DB00908,Quinidine
,6747817,EX2,"Mean (+/- SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: Vl, 0.37 +/- 0.09 L/kg; lambda 1, 0.094 +/- 0.009 min-1; lambda 2, 0.0015 +/- 0.0002 min-1; EX2, 0.013 +/- 0.002 min-1; clearance (ClQ), 3.86 +/- 0.83 ml/min/kg.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.013,193069,DB00908,Quinidine
,6747817,clearance (ClQ),"Mean (+/- SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: Vl, 0.37 +/- 0.09 L/kg; lambda 1, 0.094 +/- 0.009 min-1; lambda 2, 0.0015 +/- 0.0002 min-1; EX2, 0.013 +/- 0.002 min-1; clearance (ClQ), 3.86 +/- 0.83 ml/min/kg.",Pharmacokinetics of quinidine and three of its metabolites in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[ml] / [kgÂ·min],3.86,193070,DB00908,Quinidine
,6747817,formation rate constant kmf,"Mean (+/- SD) values for the metabolites after i.v. quinidine infusion were as follows: 3-hydroxy quinidine: formation rate constant kmf, 0.0012 +/- 0.0005 min-1, volume of distribution, Vm, 0.99 +/- 0.47 L/kg; and elimination rate constant, kmu 0.0030 +/- 0.0002 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.0012,193071,DB00908,Quinidine
,6747817,"volume of distribution, Vm","Mean (+/- SD) values for the metabolites after i.v. quinidine infusion were as follows: 3-hydroxy quinidine: formation rate constant kmf, 0.0012 +/- 0.0005 min-1, volume of distribution, Vm, 0.99 +/- 0.47 L/kg; and elimination rate constant, kmu 0.0030 +/- 0.0002 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[l] / [kg],0.99,193072,DB00908,Quinidine
,6747817,"elimination rate constant, kmu","Mean (+/- SD) values for the metabolites after i.v. quinidine infusion were as follows: 3-hydroxy quinidine: formation rate constant kmf, 0.0012 +/- 0.0005 min-1, volume of distribution, Vm, 0.99 +/- 0.47 L/kg; and elimination rate constant, kmu 0.0030 +/- 0.0002 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.0030,193073,DB00908,Quinidine
,6747817,kmf,"Quinidine N-oxide: kmf, 0.00012 +/- 0.00003 min-1; Vm, 0.068 +/- 0.020 L/kg; and kmu, 0.0063 +/- 0.0008 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.00012,193074,DB00908,Quinidine
,6747817,Vm,"Quinidine N-oxide: kmf, 0.00012 +/- 0.00003 min-1; Vm, 0.068 +/- 0.020 L/kg; and kmu, 0.0063 +/- 0.0008 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[l] / [kg],0.068,193075,DB00908,Quinidine
,6747817,kmu,"Quinidine N-oxide: kmf, 0.00012 +/- 0.00003 min-1; Vm, 0.068 +/- 0.020 L/kg; and kmu, 0.0063 +/- 0.0008 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.0063,193076,DB00908,Quinidine
,6747817,kmf,"Quinidine 10,11-dihydrodiol: kmf, 0.0003 +/- 0.0001 min-1; Vm, 0.43 +/- 0.29 L/kg; and kmu, 0.0059 +/- 0.0010 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.0003,193077,DB00908,Quinidine
,6747817,Vm,"Quinidine 10,11-dihydrodiol: kmf, 0.0003 +/- 0.0001 min-1; Vm, 0.43 +/- 0.29 L/kg; and kmu, 0.0059 +/- 0.0010 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),[l] / [kg],0.43,193078,DB00908,Quinidine
,6747817,kmu,"Quinidine 10,11-dihydrodiol: kmf, 0.0003 +/- 0.0001 min-1; Vm, 0.43 +/- 0.29 L/kg; and kmu, 0.0059 +/- 0.0010 min-1.",Pharmacokinetics of quinidine and three of its metabolites in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),1/[min],0.0059,193079,DB00908,Quinidine
,6747817,bioavailability,Oral absorption of quinidine was described by a zero order process with a bioavailability of 0.78.,Pharmacokinetics of quinidine and three of its metabolites in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747817/),,0.78,193080,DB00908,Quinidine
up to,22283559,AU,"In group 1 (n = 14), addition of DMQ to paroxetine resulted in a 30% increase in mean plasma exposure of paroxetine (AUC up to 24 hours).",Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283559/),h,24,196520,DB00908,Quinidine
,7309901,volume of distribution,"Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg).",Impairment of digoxin clearance by coadministration of quinidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309901/),[l] / [kg],15.1,197240,DB00908,Quinidine
,7309901,volume of distribution,"Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg).",Impairment of digoxin clearance by coadministration of quinidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309901/),[l] / [kg],12.4,197241,DB00908,Quinidine
,7309901,elimination half-life,"Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg).",Impairment of digoxin clearance by coadministration of quinidine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309901/),h,47.7,197242,DB00908,Quinidine
,7309901,elimination half-life,"Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg).",Impairment of digoxin clearance by coadministration of quinidine. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309901/),h,75.7,197243,DB00908,Quinidine
,7309901,total clearance,"Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg).",Impairment of digoxin clearance by coadministration of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309901/),[ml] / [kgÂ·min],6.06,197244,DB00908,Quinidine
,7309901,total clearance,"Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg).",Impairment of digoxin clearance by coadministration of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309901/),[ml] / [kgÂ·min],2.18,197245,DB00908,Quinidine
,8729890,trough serum quinidine concentration (SQC),A trough serum quinidine concentration (SQC) on day 7 was 6.3 micrograms/mL (normal 2-5) with normal QT and QTc intervals.,Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729890/),[Î¼g] / [ml],6.3,198923,DB00908,Quinidine
,7297019,bioavailability,Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (+/- S.D.) 73.5 +/- 8.6% and 79.5 +/- 22.6% (P greater than 0.05) for serum and 69.8 +/- 6.8% and 70.2 +/- 10.5% (P greater than 0.05) for urine.,Digoxin bioavailability during quinidine administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297019/),%,73.5,199690,DB00908,Quinidine
,7297019,bioavailability,Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (+/- S.D.) 73.5 +/- 8.6% and 79.5 +/- 22.6% (P greater than 0.05) for serum and 69.8 +/- 6.8% and 70.2 +/- 10.5% (P greater than 0.05) for urine.,Digoxin bioavailability during quinidine administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297019/),%,79.5,199691,DB00908,Quinidine
,7297019,bioavailability,Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (+/- S.D.) 73.5 +/- 8.6% and 79.5 +/- 22.6% (P greater than 0.05) for serum and 69.8 +/- 6.8% and 70.2 +/- 10.5% (P greater than 0.05) for urine.,Digoxin bioavailability during quinidine administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297019/),%,69.8,199692,DB00908,Quinidine
,7297019,bioavailability,Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (+/- S.D.) 73.5 +/- 8.6% and 79.5 +/- 22.6% (P greater than 0.05) for serum and 69.8 +/- 6.8% and 70.2 +/- 10.5% (P greater than 0.05) for urine.,Digoxin bioavailability during quinidine administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297019/),%,70.2,199693,DB00908,Quinidine
,7448345,bioavailability,"Quinidine was absorbed significantly more rapidly from one of the formulations than the other two; the bioavailability of this formulation, calculated from intact drug data, normalized for subject differences, was also significantly greater than that of the other two, 68 and 76 per cent respectively.",Relative bioavailability of three commercial quinidine dosage forms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448345/),%,68,201980,DB00908,Quinidine
,7448345,bioavailability,"Quinidine was absorbed significantly more rapidly from one of the formulations than the other two; the bioavailability of this formulation, calculated from intact drug data, normalized for subject differences, was also significantly greater than that of the other two, 68 and 76 per cent respectively.",Relative bioavailability of three commercial quinidine dosage forms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448345/),%,76,201981,DB00908,Quinidine
,12957180,recovery,The limit of determination was 10 nM for both quinine and 3-hydroxyquinine and the recovery varied between 78 and 109%.,High-performance liquid chromatographic method for the determination of quinine and 3-hydroxyquinine in blood samples dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12957180/),%,78 and 109,203746,DB00908,Quinidine
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),Î¼M,2.80,203765,DB00908,Quinidine
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),Î¼M,115,203766,DB00908,Quinidine
,7593709,t1/2,"Pretreatment of these subjects with 100 mg of quinidine, a selective inhibitor of CYP2D6, significantly suppressed the formation of dextrorphan and elevated the concentrations of dextromethorphan (t1/2, 16.4 hours).",Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593709/),h,16.4,204576,DB00908,Quinidine
,7593709,t1/2,"In poor metabolizers (N = 4) given the same dose, dextromethorphan was the major component in the plasma with a t1/2 of 29.5 hours.",Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593709/),h,29.5,204577,DB00908,Quinidine
,499306,Absorption,"Absorption of quinidine began after a variable delay, 2-8 h (mean 4.8) after fasting and 3-10 h (mean 6.1) after food.",Absorption of quinidine from an enteric-coated preparation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499306/),h,4.8,204777,DB00908,Quinidine
,499306,Absorption,"Absorption of quinidine began after a variable delay, 2-8 h (mean 4.8) after fasting and 3-10 h (mean 6.1) after food.",Absorption of quinidine from an enteric-coated preparation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499306/),h,6.1,204778,DB00908,Quinidine
,499306,Bioavailability,Bioavailability of quinidine in fasting subjects ranged from 69 to 95% (mean 83); variation was greater when doses were administered after food.,Absorption of quinidine from an enteric-coated preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499306/),,83,204779,DB00908,Quinidine
,19011672,AUCS/R ratio,The kinetic disposition of CITA was enantioselective in rats (AUCS/R ratio = 0.4).,"Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19011672/),,0.4,205323,DB00908,Quinidine
,3621768,Peak,"Peak quinidine serum concentrations of 2.7 +/- 0.8 mg/L occurred 2.5 +/- 1.1 hour after 'Quinaglute' administration, significantly higher (p less than 0.01) than concentrations of 1.6 +/- 0.4 mg/L achieved 4.2 +/- 1.1 hours following 'Biquin' dosing and 1.7 +/- 0.6 mg/L attained 3.9 +/- 2.7 hours after 'Quinidex' ingestion.",Comparative bioavailability study of three sustained release quinidine formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),[mg] / [l],2.7,206310,DB00908,Quinidine
,3621768,steady-state trough concentration,"Following multiple dosing, the mean steady-state trough concentration of quinidine was 2.06 +/- 0.56 mg/L for 'Quinidex', significantly greater (p less than 0.05) than that of 'Biquin' (1.18 +/- 0.67 mg/L) or 'Quinaglute' (1.58 +/- 0.58 mg/L).",Comparative bioavailability study of three sustained release quinidine formulations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),[mg] / [l],2.06,206311,DB00908,Quinidine
,3621768,steady-state trough concentration,"Following multiple dosing, the mean steady-state trough concentration of quinidine was 2.06 +/- 0.56 mg/L for 'Quinidex', significantly greater (p less than 0.05) than that of 'Biquin' (1.18 +/- 0.67 mg/L) or 'Quinaglute' (1.58 +/- 0.58 mg/L).",Comparative bioavailability study of three sustained release quinidine formulations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),[mg] / [l],1.18,206312,DB00908,Quinidine
,3621768,steady-state trough concentration,"Following multiple dosing, the mean steady-state trough concentration of quinidine was 2.06 +/- 0.56 mg/L for 'Quinidex', significantly greater (p less than 0.05) than that of 'Biquin' (1.18 +/- 0.67 mg/L) or 'Quinaglute' (1.58 +/- 0.58 mg/L).",Comparative bioavailability study of three sustained release quinidine formulations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),[mg] / [l],1.58,206313,DB00908,Quinidine
,3621768,first-order absorption half-lives,"Nevertheless, the absorption of 'Quinidex' was twice as prolonged as that of 'Biquin' and 'Quinaglute' regardless of model; first-order absorption half-lives were 2.83 +/- 1.02 hours, 1.25 +/- 0.6 hours and 1.43 +/- 0.88 hours, respectively.",Comparative bioavailability study of three sustained release quinidine formulations. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),h,2.83,206314,DB00908,Quinidine
,3621768,first-order absorption half-lives,"Nevertheless, the absorption of 'Quinidex' was twice as prolonged as that of 'Biquin' and 'Quinaglute' regardless of model; first-order absorption half-lives were 2.83 +/- 1.02 hours, 1.25 +/- 0.6 hours and 1.43 +/- 0.88 hours, respectively.",Comparative bioavailability study of three sustained release quinidine formulations. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),h,1.25,206315,DB00908,Quinidine
,3621768,first-order absorption half-lives,"Nevertheless, the absorption of 'Quinidex' was twice as prolonged as that of 'Biquin' and 'Quinaglute' regardless of model; first-order absorption half-lives were 2.83 +/- 1.02 hours, 1.25 +/- 0.6 hours and 1.43 +/- 0.88 hours, respectively.",Comparative bioavailability study of three sustained release quinidine formulations. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621768/),h,1.43,206316,DB00908,Quinidine
,12954187,intestinal clearance,"The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min, exhibiting a stereoselective intestinal elimination to (-)ABZSO form.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.106,208940,DB00908,Quinidine
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.079,208941,DB00908,Quinidine
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.069,208942,DB00908,Quinidine
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.065,208943,DB00908,Quinidine
,7139903,total body clearance,"Quinidine reduced the total body clearance of digoxin from 1.87 to 1.06 l/hour (p less than 0.001), and prolonged the digoxin half-life of elimination from 5.20 to 9.61 days (p less than 0.01).",Digoxin-quinidine interaction in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139903/),[l] / [h],1.87 to 1.06,209535,DB00908,Quinidine
,7139903,half-life of elimination,"Quinidine reduced the total body clearance of digoxin from 1.87 to 1.06 l/hour (p less than 0.001), and prolonged the digoxin half-life of elimination from 5.20 to 9.61 days (p less than 0.01).",Digoxin-quinidine interaction in patients with chronic renal failure. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139903/),d,5.20 to 9.61,209536,DB00908,Quinidine
,7139903,trough serum concentrations,The mean trough serum concentrations of quinidine ranged from 1.0 to 3.0 micrograms/ml.,Digoxin-quinidine interaction in patients with chronic renal failure. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139903/),[Î¼g] / [ml],1.0 to 3.0,209537,DB00908,Quinidine
,12848776,intrinsic clearance,"The intrinsic clearance of DEX estimated from the model ranged from 59 to 1536 l x h(-1), which overlapped with that extrapolated from in vitro data (12-261 l x h(-1)) and showed similar variation (26- vs. 21-fold, respectively).",Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),[l] / [h],59 to 1536,209628,DB00908,Quinidine
,12848776,intrinsic clearance,"The intrinsic clearance of DEX estimated from the model ranged from 59 to 1536 l x h(-1), which overlapped with that extrapolated from in vitro data (12-261 l x h(-1)) and showed similar variation (26- vs. 21-fold, respectively).",Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),[l] / [h],12-261,209629,DB00908,Quinidine
,12848776,inhibitory effect,The inhibitory effect of quinidine ([I]/Ki) was 19 (95% confidence interval of mean: 18-20) with an estimated average Ki of 0.017 microM.,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),,19,209630,DB00908,Quinidine
,12848776,[I]/Ki,The inhibitory effect of quinidine ([I]/Ki) was 19 (95% confidence interval of mean: 18-20) with an estimated average Ki of 0.017 microM.,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),,19,209631,DB00908,Quinidine
,12848776,Ki,The inhibitory effect of quinidine ([I]/Ki) was 19 (95% confidence interval of mean: 18-20) with an estimated average Ki of 0.017 microM.,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),Î¼M,0.017,209632,DB00908,Quinidine
,12848776,ke0,A sustained antitussive effect was related to slow removal of DEX/DOR from the effect site (ke0 = 0.07 h(-1)).,Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848776/),1/[h],0.07,209633,DB00908,Quinidine
,830196,plasma half-life (t1/2beta),"After intravenous administration, the plasma half-life (t1/2beta) was 7.8+/-0.7 h, the volume of distribution (Vd) was 3.0+/-0.5 liters/kg, and the total body clearance was 4.8+/-0.8 ml/min/kg.",Pharmacokinetic studies of quinidine in patients with arrhythmias. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/830196/),h,7.8,216917,DB00908,Quinidine
,830196,volume of distribution (Vd),"After intravenous administration, the plasma half-life (t1/2beta) was 7.8+/-0.7 h, the volume of distribution (Vd) was 3.0+/-0.5 liters/kg, and the total body clearance was 4.8+/-0.8 ml/min/kg.",Pharmacokinetic studies of quinidine in patients with arrhythmias. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/830196/),[l] / [kg],3.0,216918,DB00908,Quinidine
,830196,total body clearance,"After intravenous administration, the plasma half-life (t1/2beta) was 7.8+/-0.7 h, the volume of distribution (Vd) was 3.0+/-0.5 liters/kg, and the total body clearance was 4.8+/-0.8 ml/min/kg.",Pharmacokinetic studies of quinidine in patients with arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/830196/),[ml] / [kgÂ·min],4.8,216919,DB00908,Quinidine
,830196,renal clearance,"Quinidine was removed primarily by hepatic metabolism, with the renal clearance averaging only 1.0+/-0.2 ml/min/kg.",Pharmacokinetic studies of quinidine in patients with arrhythmias. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/830196/),[ml] / [kgÂ·min],1.0,216920,DB00908,Quinidine
,28911626,relative recoveries,"The method was validated over a concentration range of 0.1-100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%.","High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911626/),%,69,217913,DB00908,Quinidine
,28911626,relative recoveries,"The method was validated over a concentration range of 0.1-100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%.","High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911626/),%,82,217914,DB00908,Quinidine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],173,219079,DB00908,Quinidine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],20,219080,DB00908,Quinidine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],73,219081,DB00908,Quinidine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],37,219082,DB00908,Quinidine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],4,219083,DB00908,Quinidine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],5,219084,DB00908,Quinidine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],4,219085,DB00908,Quinidine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],3,219086,DB00908,Quinidine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],127,219087,DB00908,Quinidine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],1,219088,DB00908,Quinidine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],47,219089,DB00908,Quinidine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],7,219090,DB00908,Quinidine
,8841152,half-life,"The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,19.1,219662,DB00908,Quinidine
,8841152,half-life,"The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,5.6,219663,DB00908,Quinidine
,8841152,half-life,"The median dextromethorphan half-life was 19.1 hours in poor metabolizers, 5.6 hours in extensive metabolizers given quinidine, and 2.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,2.4,219664,DB00908,Quinidine
,8841152,half-life,"The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,10.1,219665,DB00908,Quinidine
,8841152,half-life,"The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,6.6,219666,DB00908,Quinidine
,8841152,half-life,"The median half-life was 10.1 hours in poor metabolizers, 6.6 hours in extensive metabolizers given quinidine, and 1.4 hours in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),h,1.4,219667,DB00908,Quinidine
,8841152,apparent partial clearance,"The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),[l] / [h],1.2,219668,DB00908,Quinidine
,8841152,apparent partial clearance,"The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),[l] / [h],78.5,219669,DB00908,Quinidine
,8841152,apparent partial clearance,"The apparent partial clearance of dextromethorphan to dextrorphan was 1.2 L/hr in poor metabolizers, 78.5 L/hr in extensive metabolizers given quinidine, and 970 L/hr in extensive metabolizers.",The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841152/),[l] / [h],970,219670,DB00908,Quinidine
,6176784,total body clearance (ClT),"The total body clearance (ClT) of quinidine, 3.58 +/- 1.96 (SD) ml/kg/min, was 56% slower than that of quinine, 8.11 +/- 3.03 ml/kg/min, with p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),[ml] / [kgÂ·min],3.58,221113,DB00908,Quinidine
,6176784,total body clearance (ClT),"The total body clearance (ClT) of quinidine, 3.58 +/- 1.96 (SD) ml/kg/min, was 56% slower than that of quinine, 8.11 +/- 3.03 ml/kg/min, with p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),[ml] / [kgÂ·min],8.11,221114,DB00908,Quinidine
,6176784,half-life (t1/2),"Quinine half-life (t1/2), 6.58 +/- 3.3 h, was 54% less than that of quinidine, 14.4 +/- 4.10 h, p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),h,6.58,221115,DB00908,Quinidine
,6176784,half-life (t1/2),"Quinine half-life (t1/2), 6.58 +/- 3.3 h, was 54% less than that of quinidine, 14.4 +/- 4.10 h, p less than 0.02.",Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176784/),h,14.4,221116,DB00908,Quinidine
,10497139,plasma elimination half-life,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),h,1.72,221539,DB00908,Quinidine
,10497139,clearance,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),[ml] / [kgÂ·min],18.2,221540,DB00908,Quinidine
,10497139,clearance,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),[ml] / [kgÂ·min],7.15,221541,DB00908,Quinidine
,15096109,ED(50),Quinidine coadministration resulted in a more than twofold increase in the area under the curve of DM with an ED(50) of approximately 2 mg/kg whereas those of total DX were only increased by 21%.,Influence of concomitant quinidine administration on dextromethorphan disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096109/),[mg] / [kg],2,222163,DB00908,Quinidine
,10381807,apparent clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],1939,223370,DB00908,Quinidine
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],162.7,223371,DB00908,Quinidine
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],52.7,223372,DB00908,Quinidine
,10381807,O,"Codeine O-demethylation was significantly reduced after quinidine in both ethnic groups; however, the absolute decrease was greater in Caucasians (115.8 +/- 25.9 ml/min versus 46.8 +/- 10.6 ml/min, respectively, p <.03).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],115.8,223373,DB00908,Quinidine
,26116989,depletion rate constant (kdep),We found that the plasma levels of the (-)-isomer were significantly lower than those of the (+)-enantiomer following i.v. administration of (Â±)-DOX to the rats and that the depletion rate constant (kdep) of (-)-DOX (0.0107Â±0.0007L/min) was significantly larger than that of (+)-DOX (kdep 0.0088Â±0.0005L/min) (p<0.05) when (Â±)-DOX was incubated with rat liver microsomes (RLMs).,The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116989/),[l] / [min],0.0107,226014,DB00908,Quinidine
,26116989,kdep,We found that the plasma levels of the (-)-isomer were significantly lower than those of the (+)-enantiomer following i.v. administration of (Â±)-DOX to the rats and that the depletion rate constant (kdep) of (-)-DOX (0.0107Â±0.0007L/min) was significantly larger than that of (+)-DOX (kdep 0.0088Â±0.0005L/min) (p<0.05) when (Â±)-DOX was incubated with rat liver microsomes (RLMs).,The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116989/),[l] / [min],0.0088,226015,DB00908,Quinidine
,2427003,elimination half-life,"The elimination half-life varies from 4.5 to nine hours, and it can be even longer in cases of renal failure or myocardial infarction.","Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427003/),h,4.5 to nine,226175,DB00908,Quinidine
,2427003,protein binding,"There exists an extremely variable degree of protein binding (10 to 70 percent), which is highly dependent on concentration.","Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427003/),%,10 to 70,226176,DB00908,Quinidine
,1941626,total clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],621,226923,DB00908,Quinidine
,1941626,total clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],471,226924,DB00908,Quinidine
,1941626,nonrenal clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],583,226925,DB00908,Quinidine
,1941626,nonrenal clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],404,226926,DB00908,Quinidine
,1941626,elimination half-life,"Moreover, quinidine increased mexiletine elimination half-life in EM from 9 +/- 1 to 11 +/- 2 h (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),h,9,226927,DB00908,Quinidine
,1941626,elimination half-life,"Moreover, quinidine increased mexiletine elimination half-life in EM from 9 +/- 1 to 11 +/- 2 h (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),h,11,226928,DB00908,Quinidine
,14650359,bioavailability,Following oral administration the bioavailability of tramadol is high (70-90%) and with new slow release preparations twice daily administration enables effective pain control.,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,70-90,227851,DB00908,Quinidine
,14650359,plasma protein binding,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,20,227852,DB00908,Quinidine
,14650359,apparent volume of distribution,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[l] / [kg],3,227853,DB00908,Quinidine
,14650359,Elimination half-lives,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),h,4.5 and 9.5,227854,DB00908,Quinidine
,14650359,total plasma clearance,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[ml] / [min],600,227855,DB00908,Quinidine
,8304970,ID50 concentration,Since the ID50 concentration for Ro11-2933 is 17.7 microM (5-12-fold less than the other modifiers) we have used isobologram analysis to demonstrate that the interaction with doxorubicin is supra-additive and cannot be explained by additive toxicity.,"Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304970/),Î¼M,17.7,228549,DB00908,Quinidine
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],35,229421,DB00908,Quinidine
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],7.5,229422,DB00908,Quinidine
,20233197,C(max),Concurrent ritonavir administration resulted in about fourfold increases in both the C(max) and AUC(T)[C(max) 2.79 +/- 0.22 vs.,Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,2.79,232150,DB00908,Quinidine
,20233197,AUC,"10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04; AUC 50.06 +/- 2.52 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,50.06,232151,DB00908,Quinidine
,20233197,elimination half-life,"220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),h,11.15,232152,DB00908,Quinidine
,20233197,elimination half-life,"220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),h,13.37,232153,DB00908,Quinidine
,20233197,CL/F,"220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P < 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,12.01,232154,DB00908,Quinidine
,20233197,AUC,"Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,1.35,232155,DB00908,Quinidine
,20233197,AUC,"Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,0.13,232156,DB00908,Quinidine
,20233197,C(max),"Also, with ritonavir, there was a pronounced reduction of AUC(metabolite)/AUC(unchanged drug) ratio of quinine (1.35 +/- 0.10 vs. 0.13 +/- 0.02) along with a marked decrease in C(max) (1.80 +/- 0.12 vs.",Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,1.80,232157,DB00908,Quinidine
,20233197,AUC(0-48h),0.96 +/- 0.09 mg l(-1)) and AUC(0-48h) (62.80 +/- 6.30 vs.,Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233197/),,62.80,232158,DB00908,Quinidine
,512840,V1,"Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1).",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),,0.398,233340,DB00908,Quinidine
,512840,Vdarea,"Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1).",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),[l] / [kg],2.53,233341,DB00908,Quinidine
,512840,alpha,"Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1).",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),-1Â·min,0.316,233342,DB00908,Quinidine
,512840,beta,"Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1).",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),-1Â·min,0.00204,233343,DB00908,Quinidine
,512840,k2,"Mean disposition constants (+/- SD) were obtained from individualized fits (V1: 0.398 +/- 0.336 LITER/KG, Vdarea: 2.53 +/- 0.72 liter/kg, alpha: 0.316 +/- 0.294 min -1, beta: 0.00204 +/- 0.00262 min -1, k2: 0.0305 +/- 0.0101 min -1).",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,"Î»1, Î»2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),-1Â·min,0.0305,233344,DB00908,Quinidine
,512840,clearance,A clearance of 4.9 +/- 1.5 ml/min/kg was observed.,Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),[ml] / [kgÂ·min],4.9,233345,DB00908,Quinidine
,512840,time to peak concentration,"The time to peak concentration varied from 23 to 121 min, the lag time was always less than 3 min, and the mean elimination rate constant was 0.00171 min -1.",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),min,23 to 121,233346,DB00908,Quinidine
less,512840,lag time,"The time to peak concentration varied from 23 to 121 min, the lag time was always less than 3 min, and the mean elimination rate constant was 0.00171 min -1.",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),min,3,233347,DB00908,Quinidine
,512840,elimination rate constant,"The time to peak concentration varied from 23 to 121 min, the lag time was always less than 3 min, and the mean elimination rate constant was 0.00171 min -1.",Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),-1Â·min,0.00171,233348,DB00908,Quinidine
,512840,oral bioavailability,The mean oral bioavailability of quinidine was 0.70 +/- 0.17.,Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512840/),,0.70,233349,DB00908,Quinidine
,7447220,elimination half-life,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),h,87.8,234262,DB00908,Quinidine
,7447220,elimination half-life,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),h,218.3,234263,DB00908,Quinidine
,7447220,total body clearance,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),[ml] / [hÂ·kg],5.01,234264,DB00908,Quinidine
,7447220,total body clearance,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),[ml] / [hÂ·kg],1.87,234265,DB00908,Quinidine
,8471402,terminal elimination half-time,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),h,5.7,234616,DB00908,Quinidine
,8471402,terminal elimination half-time,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),h,9.9,234617,DB00908,Quinidine
,8471402,volume of distribution at steady state (Vss),"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[1] / [kg],3.5,234618,DB00908,Quinidine
,8471402,volume of distribution at steady state (Vss),"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[1] / [kg],3.1,234619,DB00908,Quinidine
,8471402,% free drug,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),%,22.8,234620,DB00908,Quinidine
,8471402,% free drug,"2. The terminal elimination half-time of quinidine was shorter than that of quinine (median [range]; 5.7 [5.0-10.0] vs 9.9 [8.8-15.1] h, P < 0.01), the volume of distribution at steady state (Vss) for quinidine was larger than that for quinine (3.5 [2.5-5.6] vs 3.1 [1.8-4.1] 1 kg-1; P = 0.02) and quinidine was less bound to plasma proteins (% free drug: 22.8 [15.4-47.2] vs 9.4 [7.3-15.0]%, P < 0.01).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),%,9.4,234621,DB00908,Quinidine
,8471402,Total clearance,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kgÂ·min],7.7,234622,DB00908,Quinidine
,8471402,Total clearance,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kgÂ·min],3.4,234623,DB00908,Quinidine
,8471402,clearance of unbound drug,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kgÂ·min],32.2,234624,DB00908,Quinidine
,8471402,clearance of unbound drug,"Total clearance was greater for quinidine (7.7 [3.9-11.4] vs 3.4 [1.8-4.6] ml min-1 kg-1, P < 0.01) but not for clearance of unbound drug (32.2 [14.6-50.4] vs 29.9 [20.2-50.9] ml min-1 kg-1 respectively, P > 0.2).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),[ml] / [kgÂ·min],29.9,234625,DB00908,Quinidine
,8471402,keo,"4. Both drugs produced prolongation of the rate-corrected QT interval (QTc), with similar rates of elimination from the cardiac conduction 'effect' compartment (keo; 4.14 [0.03-15.33] h-1 for quinine, 3.74 [1.63-13.14] h-1 for quinidine, P > 0.19).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),1/[h],4.14,234626,DB00908,Quinidine
,8471402,keo,"4. Both drugs produced prolongation of the rate-corrected QT interval (QTc), with similar rates of elimination from the cardiac conduction 'effect' compartment (keo; 4.14 [0.03-15.33] h-1 for quinine, 3.74 [1.63-13.14] h-1 for quinidine, P > 0.19).",A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471402/),1/[h],3.74,234627,DB00908,Quinidine
,15842554,K(m),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),Î¼m,121.7,235078,DB00908,Quinidine
,15842554,V(max),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[pM] / [mgÂ·min],16.1,235079,DB00908,Quinidine
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[Î¼l] / [minÂ·nmol],0.26,235080,DB00908,Quinidine
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[Î¼l] / [minÂ·nmol],0.22,235081,DB00908,Quinidine
,15842554,nonrenal clearance,"In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.8,235082,DB00908,Quinidine
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.01,235083,DB00908,Quinidine
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,0.56,235084,DB00908,Quinidine
,1576047,clearance,"3. In five extensive metabolizer patients, quinidine significantly reduced the clearance of R-(-)-flecainide, from 395 +/- 121 (s.d.) to 335 +/- 88 ml min-1.",Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576047/),[ml] / [min],395,235218,DB00908,Quinidine
,1576047,clearance,"3. In five extensive metabolizer patients, quinidine significantly reduced the clearance of R-(-)-flecainide, from 395 +/- 121 (s.d.) to 335 +/- 88 ml min-1.",Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576047/),[ml] / [min],335,235219,DB00908,Quinidine
,499299,Absolute bioavailability,Absolute bioavailability did not differ significantly between A (median values 78.4%) and B (median 87.1%).,Absolute bioavailability of quinidine in two sustained release preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499299/),%,78.4,235587,DB00908,Quinidine
,499299,Absolute bioavailability,Absolute bioavailability did not differ significantly between A (median values 78.4%) and B (median 87.1%).,Absolute bioavailability of quinidine in two sustained release preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/499299/),%,87.1,235588,DB00908,Quinidine
,1682445,clearance (CL),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [hÂ·kg],4.49,236435,DB00908,Quinidine
,1682445,clearance (CL),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [hÂ·kg],1.38,236436,DB00908,Quinidine
,1682445,volume of distribution (Vd),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [kg],42.6,236437,DB00908,Quinidine
,1682445,volume of distribution (Vd),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [kg],28.9,236438,DB00908,Quinidine
,1682445,elimination half-life (t1/2),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,7.1,236439,DB00908,Quinidine
,1682445,elimination half-life (t1/2),"Endotoxin-induced fever in rats resulted in an increased quinine clearance (CL) (4.49 +/- 1.45 vs 1.38 +/- 0.65 L h-1 kg-1, P less than 0.001) and volume of distribution (Vd) (42.6 +/- 8.8 vs 28.9 +/- 10.3 L kg-1, P less than 0.05) with a concomitant shortening of the elimination half-life (t1/2) (7.1 +/- 2.5 vs 15.9 +/- 5.9 h, P less than 0.01).",The effect of fever on quinine and quinidine disposition in the rat. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,15.9,236440,DB00908,Quinidine
,1682445,CL,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [hÂ·kg],3.95,236441,DB00908,Quinidine
,1682445,CL,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),[l] / [hÂ·kg],1.89,236442,DB00908,Quinidine
,1682445,t1/2,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,5.1,236443,DB00908,Quinidine
,1682445,t1/2,"With quinidine, however, fever resulted in an increased CL (3.95 +/- 1.05 vs 1.89 +/- 0.60 L h-1 kg-1, P less than 0.002) with no change in Vd and a significant decrease in t1/2 (5.1 +/- 0.7 vs 10.1 +/- 2.8 h, P less than 0.001).",The effect of fever on quinine and quinidine disposition in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682445/),h,10.1,236444,DB00908,Quinidine
,3988396,t1/2 beta,The elimination half-life of high polar metabolites pool of quinidine (t1/2 beta = 6.1 h) has been determined in a quinidine phenobarbiturate intoxicated patient after the complete elimination of quinidine (its precursor) from blood.,Elimination kinetic of high polar metabolites pool of quinidine from human serum. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988396/),h,6.1,237481,DB00908,Quinidine
,3988396,t1/2 beta,"It is equivalent to the generally accepted t1/2 beta of quinidine (6.1 +/- 1.8 h) but substantially different from the t1/2 beta ""hybrid"" of 3-hydroxyquinidine (10.0 h) determined in therapeutic conditions in which 3-hydroxyquinidine coexists with quinidine in blood.",Elimination kinetic of high polar metabolites pool of quinidine from human serum. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988396/),h,6.1,237482,DB00908,Quinidine
,3988396,t1/2 beta,"It is equivalent to the generally accepted t1/2 beta of quinidine (6.1 +/- 1.8 h) but substantially different from the t1/2 beta ""hybrid"" of 3-hydroxyquinidine (10.0 h) determined in therapeutic conditions in which 3-hydroxyquinidine coexists with quinidine in blood.",Elimination kinetic of high polar metabolites pool of quinidine from human serum. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988396/),h,10.0,237483,DB00908,Quinidine
,7159686,AUC (0-46 h),"Although peak plasma quinidine levels were lower, and occurred later, after tablet administration than after solution, analysis of the area under the plasma quinidine level-time curve (AUC) values for each product indicated that the products were equivalent, in terms of the extent of absorption, with the mean AUC (0-46 h) value for the tablet, 8744 . 4 ng x h ml-1, comparable to that of the solution, 9145 . 9 ng x h ml-1.",Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159686/),[hÂ·ng] / [ml],8744 . 4,237596,DB00908,Quinidine
,7159686,AUC (0-46 h),"Although peak plasma quinidine levels were lower, and occurred later, after tablet administration than after solution, analysis of the area under the plasma quinidine level-time curve (AUC) values for each product indicated that the products were equivalent, in terms of the extent of absorption, with the mean AUC (0-46 h) value for the tablet, 8744 . 4 ng x h ml-1, comparable to that of the solution, 9145 . 9 ng x h ml-1.",Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159686/),[hÂ·ng] / [ml],9145 . 9,237597,DB00908,Quinidine
,12621387,elimination,"During rifampin, intestinal digoxin elimination was 0.80 +/- 0.59 (P =.383).",P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621387/),,0.80,239516,DB00908,Quinidine
,3593896,area under the plasma concentration-time curve (AUC),"Without dose correction, the area under the plasma concentration-time curve (AUC) for the quinidine gluconate form was 85 per cent that of the solution: an amount equivalent to the relative actual amount of quinidine base in the quinidine gluconate dosage form.",Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593896/),%,85,240690,DB00908,Quinidine
,12185554,fever clearance time,The median (range) fever clearance time was 51 h (4-152 h) and mean (SD) parasite clearance time was 74+/-28 h.,Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),h,51,240942,DB00908,Quinidine
,12185554,parasite clearance time,The median (range) fever clearance time was 51 h (4-152 h) and mean (SD) parasite clearance time was 74+/-28 h.,Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),h,74,240943,DB00908,Quinidine
,12185554,times to maximum concentrations,"The overall median times to maximum concentrations of quinine and its main metabolite 3-hydroxyquinine were 1.5 days and 4.0 days, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),d,1.5,240944,DB00908,Quinidine
,12185554,times to maximum concentrations,"The overall median times to maximum concentrations of quinine and its main metabolite 3-hydroxyquinine were 1.5 days and 4.0 days, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),d,4.0,240945,DB00908,Quinidine
,12185554,area under the plasma drug concentration-time curve to day 7 (AUC(0-7)),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[Î¼g] / [dÂ·ml],67.0,240946,DB00908,Quinidine
,12185554,area under the plasma drug concentration-time curve to day 7 (AUC(0-7)),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[Î¼g] / [dÂ·ml],51.3,240947,DB00908,Quinidine
,12185554,AUC(0-7),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[Î¼g] / [dÂ·ml],6.2,240948,DB00908,Quinidine
,12185554,AUC(0-7),"The median area under the plasma drug concentration-time curve to day 7 (AUC(0-7)) of quinine in non-smokers was 67.0 micro g/ml/day and in smokers was 51.3 micro g/ml/day, and AUC(0-7) values of 3-hydroxyquinine were 6.2 micro g/ml/day and 4.8 micro g/ml/day, respectively.",Effects of cigarette smoking on quinine pharmacokinetics in malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185554/),[Î¼g] / [dÂ·ml],4.8,240949,DB00908,Quinidine
,7146084,volume of distribution,A significant decrease in the volume of distribution for digoxin from 3.6 to 2.7 liters/kg (20%) was observed in quinidine-treated animals.,Digoxin-quinidine interaction in unanesthetized guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7146084/),[l] / [kg],3.6,241234,DB00908,Quinidine
,7146084,volume of distribution,A significant decrease in the volume of distribution for digoxin from 3.6 to 2.7 liters/kg (20%) was observed in quinidine-treated animals.,Digoxin-quinidine interaction in unanesthetized guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7146084/),[l] / [kg],2.7,241235,DB00908,Quinidine
,10381784,oral clearance,beta-Blockade had no effect on oral clearance during the high-salt diet [0.28 +/- 0.1 (quinidine + nadolol) versus 0.30 +/- 0.2 liters/h/kg (quinidine alone)] but increased clearance on the low-salt diet from 0.23 +/- 0.1 to 0.29 +/- 0.1 liters/h/kg (p <. 05).,Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381784/),[l] / [hÂ·kg],0.28,243855,DB00908,Quinidine
,10381784,oral clearance,beta-Blockade had no effect on oral clearance during the high-salt diet [0.28 +/- 0.1 (quinidine + nadolol) versus 0.30 +/- 0.2 liters/h/kg (quinidine alone)] but increased clearance on the low-salt diet from 0.23 +/- 0.1 to 0.29 +/- 0.1 liters/h/kg (p <. 05).,Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381784/),[l] / [hÂ·kg],0.30,243856,DB00908,Quinidine
,10381784,clearance,beta-Blockade had no effect on oral clearance during the high-salt diet [0.28 +/- 0.1 (quinidine + nadolol) versus 0.30 +/- 0.2 liters/h/kg (quinidine alone)] but increased clearance on the low-salt diet from 0.23 +/- 0.1 to 0.29 +/- 0.1 liters/h/kg (p <. 05).,Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381784/),[l] / [hÂ·kg],0.23,243857,DB00908,Quinidine
,10381784,clearance,beta-Blockade had no effect on oral clearance during the high-salt diet [0.28 +/- 0.1 (quinidine + nadolol) versus 0.30 +/- 0.2 liters/h/kg (quinidine alone)] but increased clearance on the low-salt diet from 0.23 +/- 0.1 to 0.29 +/- 0.1 liters/h/kg (p <. 05).,Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381784/),[l] / [hÂ·kg],0.29,243858,DB00908,Quinidine
,6832200,absorption rate constant of digoxin (ka),"In the presence of quinidine, the absorption rate constant of digoxin (ka) increased from 2.72 +/- 1.04 to 3.53 +/- 1.34 h-1 (p less than 0.05), whereas lag time and peak time decreased from 0.16 +/- 0.10 to 0.05 +/- 0.04 h (p less than 0.05) and from 0.92 +/- 0.27 to 0.69 +/- 0.19 h (p less than 0.02), respectively.",Effect of quinidine on digoxin bioavailability. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),1/[h],2.72,245752,DB00908,Quinidine
,6832200,absorption rate constant of digoxin (ka),"In the presence of quinidine, the absorption rate constant of digoxin (ka) increased from 2.72 +/- 1.04 to 3.53 +/- 1.34 h-1 (p less than 0.05), whereas lag time and peak time decreased from 0.16 +/- 0.10 to 0.05 +/- 0.04 h (p less than 0.05) and from 0.92 +/- 0.27 to 0.69 +/- 0.19 h (p less than 0.02), respectively.",Effect of quinidine on digoxin bioavailability. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),1/[h],3.53,245753,DB00908,Quinidine
,6832200,lag time,"In the presence of quinidine, the absorption rate constant of digoxin (ka) increased from 2.72 +/- 1.04 to 3.53 +/- 1.34 h-1 (p less than 0.05), whereas lag time and peak time decreased from 0.16 +/- 0.10 to 0.05 +/- 0.04 h (p less than 0.05) and from 0.92 +/- 0.27 to 0.69 +/- 0.19 h (p less than 0.02), respectively.",Effect of quinidine on digoxin bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),h,0.16,245754,DB00908,Quinidine
,6832200,peak time,"In the presence of quinidine, the absorption rate constant of digoxin (ka) increased from 2.72 +/- 1.04 to 3.53 +/- 1.34 h-1 (p less than 0.05), whereas lag time and peak time decreased from 0.16 +/- 0.10 to 0.05 +/- 0.04 h (p less than 0.05) and from 0.92 +/- 0.27 to 0.69 +/- 0.19 h (p less than 0.02), respectively.",Effect of quinidine on digoxin bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),h,0.05,245755,DB00908,Quinidine
,6832200,peak time,"In the presence of quinidine, the absorption rate constant of digoxin (ka) increased from 2.72 +/- 1.04 to 3.53 +/- 1.34 h-1 (p less than 0.05), whereas lag time and peak time decreased from 0.16 +/- 0.10 to 0.05 +/- 0.04 h (p less than 0.05) and from 0.92 +/- 0.27 to 0.69 +/- 0.19 h (p less than 0.02), respectively.",Effect of quinidine on digoxin bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),h,0.92,245756,DB00908,Quinidine
,6832200,peak time,"In the presence of quinidine, the absorption rate constant of digoxin (ka) increased from 2.72 +/- 1.04 to 3.53 +/- 1.34 h-1 (p less than 0.05), whereas lag time and peak time decreased from 0.16 +/- 0.10 to 0.05 +/- 0.04 h (p less than 0.05) and from 0.92 +/- 0.27 to 0.69 +/- 0.19 h (p less than 0.02), respectively.",Effect of quinidine on digoxin bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),h,0.69,245757,DB00908,Quinidine
,6832200,peak plasma digoxin,"Predose plasma digoxin increased from 0.41 +/- 0.25 to 0.70 +/- 0.31 ng/ml (p less than 0.02), while peak plasma digoxin increased from 0.93 +/- 0.34 to 1.63 +/- 0.46 ng/ml (p less than 0.02).",Effect of quinidine on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),[ng] / [ml],0.93,245758,DB00908,Quinidine
,6832200,peak plasma digoxin,"Predose plasma digoxin increased from 0.41 +/- 0.25 to 0.70 +/- 0.31 ng/ml (p less than 0.02), while peak plasma digoxin increased from 0.93 +/- 0.34 to 1.63 +/- 0.46 ng/ml (p less than 0.02).",Effect of quinidine on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),[ng] / [ml],1.63,245759,DB00908,Quinidine
,6832200,systemic availability,The systemic availability of digoxin increased from 68.48 +/- 13.35 to 79.09 +/- 14.89% (p less than 0.05) in the presence of quinidine.,Effect of quinidine on digoxin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),%,68.48,245760,DB00908,Quinidine
,6832200,systemic availability,The systemic availability of digoxin increased from 68.48 +/- 13.35 to 79.09 +/- 14.89% (p less than 0.05) in the presence of quinidine.,Effect of quinidine on digoxin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832200/),%,79.09,245761,DB00908,Quinidine
,14704918,Area under the curve (AUC),"Vitreal pharmacokinetic parameters of quinidine in the presence of verapamil, i.e., Area under the curve (AUC) (39.27 +/- 6.47 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,39.27,246287,DB00908,Quinidine
,14704918,maximum concentration achieved (Cmax),"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),[Î¼g] / [ml],0.095,246288,DB00908,Quinidine
,14704918,elimination half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,231.96,246289,DB00908,Quinidine
,14704918,permeation half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,16.57,246290,DB00908,Quinidine
,14704918,permeation half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,19.21,246291,DB00908,Quinidine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],8.7,247154,DB00908,Quinidine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],6.0,247155,DB00908,Quinidine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[hÂ·Î¼M] / [l],28.4,247156,DB00908,Quinidine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[hÂ·Î¼M] / [l],19,247157,DB00908,Quinidine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[hÂ·Î¼M] / [l],28.4,247158,DB00908,Quinidine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[hÂ·Î¼M] / [l],30,247159,DB00908,Quinidine
,7212478,Elimination half-life,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),h,174,247882,DB00908,Quinidine
,7212478,Elimination half-life,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),h,261,247883,DB00908,Quinidine
,7212478,total body clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [hÂ·kg],1.54,247884,DB00908,Quinidine
,7212478,total body clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [hÂ·kg],1.09,247885,DB00908,Quinidine
,7212478,renal clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [hÂ·kg],0.65,247886,DB00908,Quinidine
,7212478,renal clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [hÂ·kg],0.46,247887,DB00908,Quinidine
,11417441,elimination half-life,The median (range) quinine elimination half-life was significantly shorter after a high-salt diet [8.5 (4.3-10.2) h] than after a low-salt diet [10.0 (7.6-14.8) h] (P = 0.04).,Oral quinine pharmacokinetics and dietary salt intake. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417441/),h,8.5,248325,DB00908,Quinidine
,11417441,elimination half-life,The median (range) quinine elimination half-life was significantly shorter after a high-salt diet [8.5 (4.3-10.2) h] than after a low-salt diet [10.0 (7.6-14.8) h] (P = 0.04).,Oral quinine pharmacokinetics and dietary salt intake. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417441/),h,10.0,248326,DB00908,Quinidine
,2496225,systemic clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],935,251484,DB00908,Quinidine
,2496225,systemic clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],190,251485,DB00908,Quinidine
,2496225,nonrenal clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],782,251486,DB00908,Quinidine
,2496225,nonrenal clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],95,251487,DB00908,Quinidine
,2496225,elimination half-life,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),h,1.8,251488,DB00908,Quinidine
,2496225,elimination half-life,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),h,7.7,251489,DB00908,Quinidine
,2496225,fractional urinary recovery,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),%,17.5,251490,DB00908,Quinidine
,2496225,fractional urinary recovery,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),%,47.4,251491,DB00908,Quinidine
,17652181,K(i),"In vitro study has demonstrated that cinacalcet is a potent inhibitor of cytochrome P450 (CYP) 2D6 with a K(i) value of 0.087 micromol/L, which is comparable to the well-known potent CYP2D6 inhibitor, quinidine (0.064 micromol/L).","Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652181/),[Î¼M] / [l],0.087,255651,DB00908,Quinidine
,17652181,K(i),"In vitro study has demonstrated that cinacalcet is a potent inhibitor of cytochrome P450 (CYP) 2D6 with a K(i) value of 0.087 micromol/L, which is comparable to the well-known potent CYP2D6 inhibitor, quinidine (0.064 micromol/L).","Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652181/),[Î¼M] / [l],0.064,255652,DB00908,Quinidine
,21671,peak concentration,The peak concentration was 5.2 +/- 0.5 mumol/l for preparation A and 4.1 +/- 0.4 mumol/l for B.,Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21671/),[Î¼M] / [l],5.2,255746,DB00908,Quinidine
,21671,peak concentration,The peak concentration was 5.2 +/- 0.5 mumol/l for preparation A and 4.1 +/- 0.4 mumol/l for B.,Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21671/),[Î¼M] / [l],4.1,255747,DB00908,Quinidine
,21671,area under the plasma concentration curve (AUC),"A similar difference was found in the area under the plasma concentration curve (AUC), which was 68 +/- 10 mumol-h/l and 54 +/- 5 mumol-h/l, respectively.",Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21671/),[mumol-h] / [l],68,255748,DB00908,Quinidine
,21671,area under the plasma concentration curve (AUC),"A similar difference was found in the area under the plasma concentration curve (AUC), which was 68 +/- 10 mumol-h/l and 54 +/- 5 mumol-h/l, respectively.",Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21671/),[mumol-h] / [l],54,255749,DB00908,Quinidine
,15909533,flow rate,"Samples were eluted with a mobile phase containing acetonitrile-methanol-tetrahydrofuran-20 mM K2HPO4 (pH 7.0) (24:20:10:946, v/v), and the flow rate of the mobile phase was 1 ml/min.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),[ml] / [min],1,256164,DB00908,Quinidine
,15909533,bile-to-blood distribution ratio (AUC(bile)/AUC(blood)),"The bile-to-blood distribution ratio (AUC(bile)/AUC(blood)) was 9.8 +/- 1.9 and 13.9 +/- 3.8 at the dosages of 10 and 30 mg/kg, respectively.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),,9.8,256165,DB00908,Quinidine
,15909533,bile-to-blood distribution ratio (AUC(bile)/AUC(blood)),"The bile-to-blood distribution ratio (AUC(bile)/AUC(blood)) was 9.8 +/- 1.9 and 13.9 +/- 3.8 at the dosages of 10 and 30 mg/kg, respectively.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),,13.9,256166,DB00908,Quinidine
,33641805,IC50,"IC50 values were 1.6 Î¼M and 0.056 Î¼M with canine and feline microsomes, respectively.",Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),Î¼M,1.6,259121,DB00908,Quinidine
,33641805,IC50,"IC50 values were 1.6 Î¼M and 0.056 Î¼M with canine and feline microsomes, respectively.",Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),Î¼M,0.056,259122,DB00908,Quinidine
,33641805,Total body clearance (ClB),"Total body clearance (ClB) of cimicoxib, was 0.50 L/h kg in dogs and 0.14 L/h kg in cats (P < 0.01) and terminal half-life, TÂ½Î»z, was 1.92 and 5.25 h, respectively (P < 0.01).",Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),[l] / [hÂ·kg],0.50,259123,DB00908,Quinidine
,33641805,Total body clearance (ClB),"Total body clearance (ClB) of cimicoxib, was 0.50 L/h kg in dogs and 0.14 L/h kg in cats (P < 0.01) and terminal half-life, TÂ½Î»z, was 1.92 and 5.25 h, respectively (P < 0.01).",Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),[l] / [hÂ·kg],0.14,259124,DB00908,Quinidine
,33641805,"terminal half-life, TÂ½Î»z","Total body clearance (ClB) of cimicoxib, was 0.50 L/h kg in dogs and 0.14 L/h kg in cats (P < 0.01) and terminal half-life, TÂ½Î»z, was 1.92 and 5.25 h, respectively (P < 0.01).",Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),h,1.92,259125,DB00908,Quinidine
,33641805,"terminal half-life, TÂ½Î»z","Total body clearance (ClB) of cimicoxib, was 0.50 L/h kg in dogs and 0.14 L/h kg in cats (P < 0.01) and terminal half-life, TÂ½Î»z, was 1.92 and 5.25 h, respectively (P < 0.01).",Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),h,5.25,259126,DB00908,Quinidine
,33641805,Dose eliminated in urine,Dose eliminated in urine was 12.2% in dogs and 3.12% in cats (P < 0.01).,Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),%,12.2,259127,DB00908,Quinidine
,33641805,Dose eliminated in urine,Dose eliminated in urine was 12.2% in dogs and 3.12% in cats (P < 0.01).,Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641805/),%,3.12,259128,DB00908,Quinidine
,2316233,area under the concentration-time curve (AUC),"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),[hÂ·mg] / [l],23.11,261161,DB00908,Quinidine
,2316233,time to reach maximum concentration (tmax),"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),h,3.13,261162,DB00908,Quinidine
,2316233,maximum serum concentration,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),[mg] / [l],1.44,261163,DB00908,Quinidine
,2316233,maximum serum concentration,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),[hÂ·mg] / [l],23.91,261164,DB00908,Quinidine
,2316233,maximum serum concentration,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),h,4.13,261165,DB00908,Quinidine
,2316233,elimination rate constant,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),,0.069,261166,DB00908,Quinidine
,19530072,apparent influx clearance,The apparent influx clearance of [(3)H]naloxone across the BBB was 0.305 mL/min/g brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brainÂ·gÂ·min],0.305,261249,DB00908,Quinidine
,19530072,apparent elimination half-life,[(3)H]naloxone was eliminated from the brain with an apparent elimination half-life of 15.1 min after microinjection into the parietal cortex area 2 regions of the rat brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),min,15.1,261250,DB00908,Quinidine
,19530072,apparent efflux clearance,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brainÂ·gÂ·min],0.152,261251,DB00908,Quinidine
,19530072,elimination rate constant,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),1/[min],4.79 x 10(-2),261252,DB00908,Quinidine
,19530072,distribution volume,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brainÂ·g],3.18,261253,DB00908,Quinidine
,6473899,B max,Specific binding of digoxin was documented in the renal slices with B max of 42.34 pmol/gr and Kd of 7.6 pmol/gr.,Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473899/),[pM] / [gr],42.34,261949,DB00908,Quinidine
,6473899,Kd,Specific binding of digoxin was documented in the renal slices with B max of 42.34 pmol/gr and Kd of 7.6 pmol/gr.,Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473899/),[pM] / [gr],7.6,261950,DB00908,Quinidine
,6473899,maximal concentration,Further increase in verapamil concentration resulted in additional reduction in digoxin uptake; the maximal concentration used (42 microM) caused 60% decrease in uptake (p less than 0.0001).,Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473899/),Î¼M,42,261951,DB00908,Quinidine
,7966546,relative bioavailability,The relative bioavailability of the oral solution under fed conditions in comparison to the solution under non-fed conditions was 75.0 +/- 10.2% for the loading dose and 97.18 +/- 31.66% after the fourth dose.,Effect of drug formulation and feeding on the pharmacokinetics of orally administered quinidine in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7966546/),%,75.0,262692,DB00908,Quinidine
,7966546,relative bioavailability,The relative bioavailability of the oral solution under fed conditions in comparison to the solution under non-fed conditions was 75.0 +/- 10.2% for the loading dose and 97.18 +/- 31.66% after the fourth dose.,Effect of drug formulation and feeding on the pharmacokinetics of orally administered quinidine in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7966546/),%,97.18,262693,DB00908,Quinidine
,3451957,plasma concentration,"The plasma concentration of quinidine at steady state, after an intravenous injection (20 mg/kg body weight) followed by a constant rate infusion (0.2 mg/min/kg), increased from 3.02 to 5.11 micrograms/ml after cimetidine treatment.",Effects of cimetidine on quinidine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3451957/),[Î¼g] / [ml],3.02,264199,DB00908,Quinidine
,3451957,plasma concentration,"The plasma concentration of quinidine at steady state, after an intravenous injection (20 mg/kg body weight) followed by a constant rate infusion (0.2 mg/min/kg), increased from 3.02 to 5.11 micrograms/ml after cimetidine treatment.",Effects of cimetidine on quinidine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3451957/),[Î¼g] / [ml],5.11,264200,DB00908,Quinidine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[hÂ·ng] / [ml],6470,266472,DB00908,Quinidine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[hÂ·ng] / [ml],3822,266473,DB00908,Quinidine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[hÂ·ng] / [ml],6642,266474,DB00908,Quinidine
,1979624,AUC,"Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[hÂ·ng] / [ml],4808,266475,DB00908,Quinidine
,1979624,clearance (CL),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [gÂ·min],0.33,266476,DB00908,Quinidine
,1979624,clearance (CL),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [gÂ·min],0.64,266477,DB00908,Quinidine
,1979624,volume of distribution (Vd),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [g],53.0,266478,DB00908,Quinidine
,1979624,volume of distribution (Vd),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),[ml] / [g],81.2,266479,DB00908,Quinidine
,1979624,elimination half-life (t1/2),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),h,1.93,266480,DB00908,Quinidine
,1979624,elimination half-life (t1/2),"MI resulted in decreased quinine clearance (CL) (0.33 +/- 0.08 vs 0.64 +/- 0.09 mL min-1 g-1, P less than 0.001) and volume of distribution (Vd) (53.0 +/- 13.3 vs 81.2 +/- 23.7 mL g-1, P less than 0.05) but no significant change in elimination half-life (t1/2) (1.93 +/- 0.6 vs 1.37 +/- 0.25 h, P greater than 0.05).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),h,1.37,266481,DB00908,Quinidine
,1979624,CL,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,0.38,266482,DB00908,Quinidine
,1979624,CL,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,0.64,266483,DB00908,Quinidine
,1979624,t1/2,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,1.62,266484,DB00908,Quinidine
,1979624,t1/2,"With quinidine, however, MI resulted in decreased CL (0.38 +/- 0.16 vs 0.64 +/- 0.09, P less than 0.05) with no change in Vd and a significant increase in t1/2 (1.62 +/- 0.42 vs 0.88 +/- 0.22, P less than 0.01).",The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979624/),,0.88,266485,DB00908,Quinidine
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.07,268540,DB00908,Quinidine
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.92,268541,DB00908,Quinidine
< or =,18855612,F(G),"An area of high intestinal extraction (F(G) < or = 0.25) is identified as problematic, as availability of conclusive data is limited in this area.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.25,268542,DB00908,Quinidine
,6520745,half-life,After PB pretreatment plasma quinidine concentrations at the end of a 10 hr infusion increased about twofold while the half-life decreased from a control value of about 16 hr to 6 hr.,Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),h,16,269134,DB00908,Quinidine
,6520745,half-life,After PB pretreatment plasma quinidine concentrations at the end of a 10 hr infusion increased about twofold while the half-life decreased from a control value of about 16 hr to 6 hr.,Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),h,6,269135,DB00908,Quinidine
,6520745,steady-state volume of distribution (Vdss),"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),l,153,269136,DB00908,Quinidine
,6520745,steady-state volume of distribution (Vdss),"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),l,54,269137,DB00908,Quinidine
,6520745,total clearance,"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),[l] / [h],6.6,269138,DB00908,Quinidine
,6520745,total clearance,"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),[l] / [h],5.6,269139,DB00908,Quinidine
<,17470526,brain-to-serum ratio,"Brain distribution of CP-615,003 and CP-900,725 was low in rats and mice (brain-to-serum ratio < 0.2).","Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470526/),,0.2,269514,DB00908,Quinidine
